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Abstract 
This thesis describes the application of lipase mediated kinetic resolutions in the 
synthesis of two biologically active and pharmaceutically important compounds:- 
Bufuralol has activity as a beta-blocker and recently it has become useful in 
metabolism studies as a substrate for a specific cytochrome P450 enzyme. Chapter 
three details how bufuralol, formerly marketed as a racemate, can be conveniently 
prepared in optically enriched form with a lipase resolution of a precursor as the key 
step. 
Methadone is currently used worldwide as a treatment in the maintenance of 
patients with addictions to opiates. It is mainly administered as a racemic mixture 
although the activity of the drug is due to the levorotatory isomer only. Levo-
methadone can be efficiently prepared by employing a lipase in the resolution of 1-
dimethylamino-2-propanol which is an inexpensive starting material for the 
synthesis of methadone. This is described in chapter four. Since both isomers of 1-
dimethylamino-2-propanol are isolated from the resolution dextro-methadone may 
also be prepared and although it shows little or no activity itself, dextro-methadone 
may be converted in two steps to levo-a-acetylmethadol which is used in the U.S. as 
a longer acting alternative to methadone. 
'U 
The Teaching Company Scheme 
This PhD was partly funded by the BBSRC as part of a Teaching Company Scheme 
(TCS) between the University of Edinburgh and UFC Ltd, Manchester (Ultrafine). 
The Teaching Company Scheme is a relatively unusual means by which to fund a 
higher degree in the sciences and it is appropriate to give a brief account explaining 
what a Teaching Company Scheme is and how it works. 
Teaching Company was originally set up as a means of training engineering 
graduates in management and general commercial awareness within the workplace - 
the teaching company. The name "Teaching Company" comes from an analogy with 
the teaching hospital for students of medicine. The graduate or Teaching Company 
Associate (TCA) is given a placement in a company and a project to undertake over a 
period of two to three years. The project involves the transfer of new technology 
from an academic institution to the company and the TCA is supported in this task 
by an academic supervisor (expert in the field) and an industrial supervisor 
(manager - mentor). Also, a consultant from the Teaching Company Directorate 
(TCD) oversees the whole project. The TCA is based at the company for the most 
part and occasionally spends some time at the University when necessary. In terms 
of time spent in industry and time spent in academia a TCS may be considered to be 
opposite to an industrially sponsored CASE studentship. The TCA also attends 
various management training courses which are organised by the TCD. If the project 
is suitable then the TCA may register for a higher degree 
Over the last few years an increasing number of Teaching Company Schemes have 
been set up which are science based allowing science graduates to benefit from this 
new method of training and science companies to aquire new technologies being 
iv 
developed at universities. The TCS between The University of Edinburgh and 
Ultrafine was set up to develop biotransformations as a new technology within 
Ultrafine. In fact this scheme was just the first of now three TCSs between Edinburgh 
and Ultrafine and currently Dr Stuart Brown is setting up a designated 
biotransformations laboratory at Ultrafine in which he will be able to handle 
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There has been much interest over the past 10-15 years in the use of enzymes 
as catalysts for synthesis. In particular, due to the fact that enzymes provide 
their substrates with a unique chiral environment, they have been used 
extensively for the manufacture of optically active materials. Enzymes offer 
many advantages over more conventional techniques 
I) They can catalyse many different organic transformations 
ii) They show high selectivity for - 
a particular functional group (chemoselective) 
the relative position of this group (regioselective) 
the absolute configuration of the group (enantioselective) 
iii) They have a broad substrate tolerance 
iv) They can be used under mild conditions 
This thesis will concentrate on the application of lipases. Lipases are very 
versatile biocatalysts as they may be used in impure form without the need 
for expensive or unstable cofactors. These features allow them to be used 
economically and efficiently for large scale applications (as will be shown). 
Often lipases are used immobilised on a suitable support and this improves 
there ease of use as they can be easily filtered and recovered for re-use. 
Chapter 1 will discuss firstly the mode of action of lipases and show how 
various investigators have revealed some detail of the mechanism of action 
and active site of these enzymes, secondly the many ways in which lipases 
have been used to prepare optically active materials will be reviewed, and 
finally some industrial applications of enzyme catalysis will be discussed. 
Introduction 
1.1 Lipases - How they work 
In nature, lipases are used to break down triacylglycerides into free fatty acids 
and glycerols - they catalyse the hydrolysis of ester bonds. In the laboratory, 
lipases can be used both for the hydrolysis of esters and the esterification of 
alcohols in the presence of a suitable acyl donor i.e. they can act reversibly. 
The mechanism of action of all lipases is very similar and they are classed as 
serine esterases. Scheme 1 shows the mechanism for human pancreatic lipase 
as a representative example. 1,2  
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The active site of the enzyme consists of three amino acid residues known as 
the catalytic triad, namely aspartic acid-176, histidine-263 and serine-152. 
Hydrogen bonds are set up between these residues which increase the 
nucleophilicity of the oxygen of the serine and this can then attack the scissile 
ester bond forming a tetrahedral intermediate, 1. After displacement of the 
alcohol, ROH by water (for hydrolysis) the catalytic triad act together again 
so that histidine deprotonates the water and at the same time releases a 
proton to Asp-176. The activated -OH can attack the acylserine giving a 
second tetrahedral intermediate, 2. This intermediate can then breakdown to 
give the acid and regenerate the serine-OH so that the catalytic cycle can start 
again. In principle then, one molecule of enzyme can hydrolyse a large 
number of substrate ester molecules and this hydrolysis takes place in the 
specific chiral environment of the active site. Another important property of 
the active site is that there are no solvent molecules present which may 
otherwise solvate the activated species and lead to slower reactivity. 
In order to understand more about the geometry around the active site, 
several workers began probing these enzymes with many different substrate 
molecules. This approach is known as substrate mapping. They developed a 
picture of the catalytic site and the area around it by changing the sizes and 
functionalities of the groups around the reactive centre of the substrate 
molecule and observing what effect this had on the rate of conversion and the 
enantiomeric purity of the products. By employing this empirical approach a 
reasonably accurate picture of the region around the catalytic site is 
obtained. 3 '4  It was found that the best substrates are those which have a 
substantial difference between the sizes of the two groups around the reactive 
centre (Figure 1). Also, the favoured enantiomer is that shown in Figure 1, and 
provided that the large group (L) has a higher priority over the small group 







Over the past few years the high resolution X-ray crystal structures of several 
lipases have been reported including Rhizoniucor niiehei lipase,5 and human 
pancreatic lipase. 2 These publications report the presence of a lid or flap 
which covers the catalytic site of these enzymes. A conformational change 
occurs at a lipid-water interface causing the lid to move and exposing the 
active site to the substrate molecule. It is thought that this is a common 
property of many lipolytic enzymes. It is also noted that once the lid is 
opened the area around the active site becomes more non-polar due to the 
hydrophobic residues on the underside of the lid being exposed, and this 
activated configuration is stabilised in an organic environment. 
The group of Kaslauskas et aL, 6 have examined the active site of Candida 
iii gosa lipase and have established the mechanism by which this enzyme 
distinguishes between enantiomers. They used phosphonate analogs of (R) 
and (S)-menthyl esters to form covalently bound complexes with the lipase 
(Figure 2). Examination of each of these complexes in turn gave an 
understanding of why the (R)-menthyl ester is preferred. 
in 
lii ftodiiction 
Figure 2 The X-ray crystal structure of Candida ullgOSU lipase with 
(R)-nenthy1 hexyl phosphonate bound to the active site. 
(5)-menthol 
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The X-ray crystal structure analysis of the (R)-menthyl phosphonate bound to 
the lipase showed that the histidine residue in the catalytic triad is at a 
suitable distance to form hydrogen bonds with the serine group and the 
menthol oxygen (Figure 3). On the other hand, when the menthyl 
phosphonate has (5)-stereochemistry the isopropyl group points towards the 
imidazole ring of the histidine causing it to twist away and the distance to the 
menthol oxygen is too great (4.36A) to form a hydrogen bond. The disruption 
of this hydrogen bond explains the much slower reactivity of the (5)-
enantiomer of menthol. These workers go on to suggest that the 
enantiop reference of Candida rugosa lipase is due to the orientation of the 
catalytic triad and that this is very similar in other lipases. This is therefore a 











Figure 3 Schematic diagram showing the hydrogen bonding between the 
imidazole of the catalytic triad and the (R) and (S)-menthyl phosphonates 
1.2 Lipase catalysed transformation of meso-substrates 
Lipases are particularly effective catalysts for the transformation of prochiral 
or mesa-substrates. The substrate is accommodated within the active site of the 
Introduction 
enzyme so that only one of two enantiotopic groups can be transformed 
thereby creating an asymmetric centre in the molecule. As the substrate 
adopts an optimum geometry within the chiral environment of the active site 
it is, in theory, possible for the enzyme to convert an achiral compound into 
an optically pure product. The great advantage that this has over enzymic 
resolution of racemic compounds is that all of the substrate can be converted, 
theoretically, to a product with the same stereochemical configuration and 
therefore there are no difficulties in separating products with opposite 
stereochemistries as is the case in resolution procedures. 
A wide range of substrates have been transformed into useful optically active 
building blocks using this type of technology. This work was originally 
developed by Sih et al.,7 in their preparation of (R) and (S)-mevalonic acids 
(Scheme 2). 
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Here, the pro (R)-methyl ester group of 3 is selectively hydrolysed to give the 
asymmetric half ester 4. 
Several other groups have used a similar approach in the preparation of chiral 
building blocks for the total synthesis of various natural products. 8'9'10 Xie et 
al., have reported that 1,3-diacetoxy-2-methylpropane is a good substrate for 
Pseudoinonasjluorescens lipase. 8'9 The reaction was allowed to proceed to 33% 
chemical conversion and the monoacetate 5 is obtained with ee >99%. The 
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unreacted diacetate is recovered. The conversion of 5 to a chiral C-5 
isoprenoid, 10 is described which is itself a common unit in natural products 
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Scheme 3 
Firstly, the alcohol functionality was protected as the tetrahydropyran-2-yl 
ether 6. The acetate ester was then hydrolysed and the alcohol produced 7 
was treated with mesyl chloride in pyridine to give the mesylate 8. 
Conversion to the nitrile precursor 9 was effected by the reaction with sodium 
cyanide in DMSO. The THP group was removed with aqueous acetic acid and 
bromination was achieved by the reaction with allyl bromide and 
carbonyldiimidazole. (S)-4-Bromo-3-methylbutanenitrile 10 was thus obtained 
from the homochiral monoacetate 5 in 41% overall yield. 
The preparation of (-)-muscone 16, from this C-5 unit is also shown 9  using a 
novel three carbon ring expansion (Scheme 4). 
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Dodecanone, 11 was treated with LDA and the resulting enolate was reacted 
with ethyl cyanoformate to give the 3-keto ester 12. This was easily 
deprotonated with potassium tert-butoxide to give a second enolate which 
condensed with the chiral isoprenoid 10 to produce 13. Further treatment 
with potassium tert-butoxide gave the three carbon ring expanded product 14. 
Acid hydrolysis of the nitrile group with subsequent decarboxylation together 
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with hydrolysis of the ester functionality produced the 1,5-ketoacid. This was 
reduced to the alcohol with lithium aluminiumhydride and re-oxidised to 
give the aldehyde 15 by treatment with pyridinium chlorochromate. Finally, 
deformylation of 15 with Wilkinson's complex afforded (-)-muscone 16. 
This example of a natural product synthesis employs a lipase catalysed 
desymmetrisation of a prochiral substrate as the method of choice for the 
generation of the asymmetric centre. 
Mori and Chiba 10 used a similar strategy for the synthesis of (S)-(-)-paraconic 
acid. They initially looked at the hydrolysis of two substrates, 17 and 18 




The use of porcine pancreatic lipase gave the best results with the diacetate 18. 
The reaction was carried out in 30% aqueous acetone at pH 7 and the (R)-half 
ester, 19 was obtained in 56% yield with cc 86%. This was then oxidised with 
chromic acid to give the acid 20. Ozonolysis with oxidative work up afforded 
(S)-(+)-2-(acetoxymethyl)succinic acid 21 and treatment with dilute 
hydrochloric acid produced (S)-(-)-paraconic acid, 22 (Scheme 5). Absolute 
optical purity was achieved by crystallisation of its (R)-(+)-a-phenethylamine 
salt. Mori and Chiba stated that the classical resolution of racemic paraconic 
acid using either (S) or (R)-c(-phenethylamine gave a very poor yield of the 
pure enantiomer and the use of this lipase catalysed asymmetric hydrolysis of 
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Scheme 5 
The regioselective acetylation of nieso-diols, the reverse process, has been 
studied with the same substrate (Scheme 6).1112 
Scheme 6 
Again the (R)-half ester, 19 is obtained with high ee (>94%) but this time the 
yield is quoted as being quantitative. In the same series of compounds the 
2-triethyipropanediol has been acetylated in relatively poor yield and low 
enantiomeric excess. 12 However, this substrate has been studied further by 
11 
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Santaniello et al.,13 who discovered that the reaction can be pushed further to 
give a 40:60 mixture of monoacetate and diacetate with no remaining diol. 
The monoacetate isolated from this has an ee>98%. It is suggested that this is 
because the real substrate for the lipase is in fact the monoacetate which is 
resolved by the enzyme. The report confirms this by showing the results of an 
experiment in which the racemic monoacetate is treated with vinyl acetate in 
the presence of Pseudornonasfiuorescens lipase. Here, the unreacted 
monoacetate is isolated in 40% yield with ee>98%. 
Cyclopentene-1,4-diol can be converted to (1S,4R)-4-hydroxycyclopent-2-enyl 
acetate in a similar fashion 14 (Scheme 7) but this time pancreatin is the 
enzyme used. Again both monoacetates are formed but only one is converted 
to the diacetate. 
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The chiral monoacetate 24 can be converted to the enone 27 which is an 
important building block for the synthesis of prostaglandins (Scheme 8). 
Firstly, the alcohol is protected as the tert-butyldimethylsilyl ether 25. Then 
hydrolysis of the acetate ester followed by oxidation gives the enone 27. This 
versatile intermediate has been used for the syntheses of several 
prostaglandins 15,16  A particularly attractive approach involves the conjugate 
addition to this enone and the subsequent trapping of the enolate produced 
with a suitable electrophile 17  Reaction with the organozinc reagent 28 gives 
exclusively the 1,4 product 29 and the stereochemistry of the attack is directed 
by the bulky tert-butyldimethylsilyl group. The product of the conjugate 
addition is held as the metal enolate and reacted with the propargylic iodide 
30. Again the stereochemistry is controlled by the neighbouring stereocentre 
and the attack by the electrophile is on the opposite face to the eight carbon 
side chain. The product 31 is then partially hydrogenated using a poisoned 
catalyst to give the precursor 32. Finally, sodium borohydride reduction of the 
ketone occurs on the less hindered face and after deprotection prostaglandin 
F2a 33 is obtained. 
This represents a simple synthesis of a complex biologically active product 
with the stereochemistry for each step being controlled by the neighbouring 
chiral centre in the molecule. Essentially then, the asymmetric centre obtained 
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The asymmetrisation of meso compounds using lipases has been successful 
using larger more complex substrates. Me et al.,8 took the meso-diacetate, 34 in 
the presence of Pseudomonusjluorescens lipase in a buffered solution and the 
monoacetate, 35 was produced in 79% yield with ee 96%.The product 35 was 
then used to synthesise the lactone 38 which has hunger modulating activities 
(Scheme 9). 
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Scheme 9 
Pyridinium dichromate oxidation of the alcohol produced the acid 36. The 
acetonide protection was removed in the presence of para-toluenesulphonic 
acid in dichloromethane and under these conditions ring closure to form the 
lactone 37 occured. The acetate was then hydrolysed with potassium 
carbonate and the lactone reformed in the presence of dilute hydrochloric 
acid. 
Heterocyclic systems can also make good substrates for regioselective lipase 
catalysed hydrolyses. Chênevert and Dickman 18 report that meso-2,6- 
15 
hit rod,., ctioi, 
substituted piperidines can be hydrolysed selectively in the presence of 
Aspergillus niger lipase (Scheme 10). 
AcO -.\\\-0-,,,/,-0Ac 
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It was noted that the addition of 5% acetonitrile improved the chemical yield 
and optical purity of the products. Also, it prevented the degradation of the 
enzyme. 
1.3 Biocatalysis in Industry 
Biocatalysis has become a core technology for many chemical firms, 
particularly pharmaceutical companies and others in the life sciences sector 
where enantiomerically pure chiral compounds are becoming more and more 
important. Indeed, biocatalysis is a key tool in the toolkit of any manufacturer 
interested in producing optically active materials. 
There are many reasons why biocatalysis is becoming such an important 
technology: 
it offers access to optically active materials. Often, alternative chemical 
routes may use patented technology such as Corey's reduction of ketones 
using chiral oxazaborolidinones 19 or Jacobsen's asymmetric epoxidations. 20 
The number of available enzymes is increasing dramatically. Also natural 
16 
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diversity is being exploited to access enzymes from different environments 
leading to the availability of biocatalysts which will tolerate a wide range of 
reaction conditions. 2 ' For example, enzymes isolated from organisms which 
live deep in the ocean will be active at high pressure. Whereas others found in 
harsh environments such as in volcanic regions are stable at high 
temperatures and low pH. 
Advances in protein technology are allowing scientists to modify enzyme 
activities by mutagenesis of specific amino acids. 22 This strategy is giving 
researchers the ability to 'fine-tune enzymes for specific purposes. 
Enzymes are now commonly available in immobilised form or, from Altus 
Biologics Inc., as CLECs - cross-linked enzyme crystals. 23 Immobilisation on 
solid support or formation of these cross linked enzyme crystals often gives 
increased activity. Also the biocatalyst can easily be filtered when the 
biotrans formation is complete and may be recycled, thus giving large cost 
savings on an industrial scale. 
In this section examples will be given of the use of biotransformations in 
industry for the production of chiral compounds. 
1.3.1 Avecia Life Science Molecules 
Avecia LSM (formerly Zeneca LSM) have developed a process for the 
manufacture of (S)-2-chloropropanoic acid ((5)-CPA) 41 using a 
biotransformation. 24 (5)-CPA is an important chiral building block and is used 
in the production of enantiopure phenoxypropanoic herbicides such as 
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Non-steroidal anti inflammatory drugs such as naproxen, ibuprofen, and 
ketoprofen all contain the same chiral propanoic acid group and so could be 
produced in optically active form using (S)-CPA. However, these compounds 
have either been marketed in the racemic form or prepared asymmetrically by 
an alternative route such as the chiral reduction of the acrylic acid using 
Noyori type asymmetric Ruthenium complexes. 25 Avecia LSM have 
themselves developed a route to (R)-2'-benzyloxy-(2,4- 
difluoro)propiophenone 44 using (S)-CPA 41 as the chiral starting material. 26 
Fj&_'Y 0"1"0 
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This material is the key intermediate for the production of antifungal 
compounds for treating immunocompromised patients such as those with 
AIDS, or those undergoing chemotherapy or organ transplant. 
Prior to the work carried out at Avecia LSM, (S)-CPA had been manufactured 
by a variety of methods. These included the fermentation of glucose using 
selected strains of lactobacillus to give (R)-lactic acid which was converted to 
Lit 
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(5)-CPA by esterification followed by chlorination. (R)-lactic acid is the 
unnatural isomer and although the bacterial strains which produce it are well 
characterised the process requires a much higher degree of fermentation 
control than that which produces the natural (5)-lactic acid. Another 
alternative synthesis is based on the lipase catalysed resolution of esters of 
CPA. However, long reaction times and a degree of conversion greater than 
60% were required to obtain good optical purity. 
Avecia LSM (then Zeneca LSM) developed an industrial scale process to 
produce (5)-CPA based on the enzymic resolution of the inexpensive racemic 
chloropropanoic acid using a dehalogenase (Scheme 12). 
CI 	 CI 	 OH (R)-CPA Dehalogenase 
+ MeCOOH 	 MeCOOH MeCOOH 
(5)-CPA 	(5)-Lactic acid 
41 
Scheme 12 
Over a period of about 8 years, a multidisciplinary team developed this 
process from conception to production of greater than one thousand tonnes 
per annum of (5)-CPA. The first problem was to find a dehalogenase which 
was specific for (R)-CPA. After screening soil samples, several strains of 
bacteria were found which were capable of dehalogenating both isomers of 
CPA. One from a Pseudomonas species, Pseudornonas putida,was found to 
contain two dehalogenases. One enzyme was specific for (R)-CPA and the 
other for (5)-CPA. These proteins were separated by ion exchange 
chromatography and the (R)-CPA specific enzyme was studied to check its 
activity under various conditions. Avecia LSM found that both the enzyme 
and the host organism were good candidates for further development work. 
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The next decision to be made was whether to use the isolated enzyme or to 
use a whole cell system. The advantage of using whole cells would be the 
avoidance of having to extract and purify the enzyme but the (S)-CPA specific 
dehalogenase would need to be inactivated before this would be a viable 
approach. This was done by chemical mutagenesis which resulted in a strain 
with no (S)-CPA dehalogenase activity. After the selection of a suitable 
initiator - monochloroacetic acid - needed to induce the expression of the 
dehalogenase enzyme, Avecia had a biotransformation process capable of 
producing one thousand tonnes per annum of (S)-CPA. 
Further development involved the use of molecular biology to identify the 
gene which encoded the (R)-CPA dehalogenase enzyme and this was 
expressed in a strain of Escherichia coli. This expressed much increased levels 
of active (R)-CPA dehalogenase and led to a 3-4 fold increase in productivity 
for the overall process. 
This example illustrates how a biotransformation can be implemented on an 
industrial scale and how several hurdles can be overcome to give a robust and 
highly economical process. 
Another example of the application of biotransformations on a commercial 
scale by Avecia LSM is in their process for producing an optically active 
intermediate used in the preparation of an anti-glaucoma drug. 24 Here a 
whole cell microorganism is used to effect an asymmetric reduction of a keto 
group (Figure 5). 
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Figure 5 
Baker's yeast or Saccharo;nyces cerevisiae is probably the most well known and 
most commonly used microorganisms to carry out asymmetric reductions of 
this type. 27 Avecia screened this organism along with more than 40 other 
species including other yeasts, bacteria and fungi in order to identify both a 
good conversion rate and good selectivity to give the trans product 46. 
A species of bacteria, Lactobacillus plantarum, gave a high percentage of the 
desired trans product but conversion rates were low. Further studies were 
carried out using this microorganism but it was found that in order to 
increase the conversion a near neutral pH was required and under these 
conditions the substrate was racemised. It was necessary to find an alternative 
microorganism which gave the required selectivity under acidic conditions. 
The fungus Neurospora crassa gave a trans:cis hydroxysulphone ratio of 71:29 
in the initial screening experiments. N. crassa was known to be active at low 
pH and when tested at pH 4.3 the product was obtained in >80% yield and 
very high diastereomeric and optical purity (>98% of the trans product 46). 
After optimisation this process was scaled up to plant scale and is proof in 
practise that biotransformations can be used commercially to produce 
complex optically pure materials. 
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1.3.2 Eli Lilly & Co. 
Eli Lilly use a similar biotransformation to the one just discussed in their 






A key step in this process is the asymmetric reduction of the ketone 48. 
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48 	 49 
After screening microbial libraries, Eli Lilly found that the yeast, 
Zygosaccharoniyces rouxii, gave good conversion to the desired (5)-alcohol 49 
with a high optical purity. However, it would only tolerate low 
concentrations of organic species: It is sometimes possible to overcome this 
problem by keeping the substrate and product separate from the active 
organism by using a two-phase system with an immiscible organic solvent. 
Unfortunately organic solvents were found to be too toxic for this particular 
yeast. 
Eli Lilly devised an ingenious solution to this problem. They found that the 
reaction could be carried out with a 7-fold increase in substrate concentration 
by using a polymeric resin - XAD-7. At the start of the reaction the ketone was 





the aqueous phase 2 gIL. The yeast was added and as the product was 
formed it was adsorbed onto the resin. The XAD-7 effectively acted as a slow 
release mechanism for the substrate and a sponge for the product and in this 
way limited the exposure of either to the Z. rouxii. Furthermore, when the 
reaction was complete, as the product was adsorbed on the large (500 gm) 
polymeric beads it was simply isolated using a suitably sized filter screen. 
This example shows how a relatively sensitive microorganism can be used to 
carry out a very stereoselective reduction on a multi-kilogram scale by the use 
of some clever process engineering. 
1.3.3 Chiroscience 
Chiroscience (now Ascot Fine Chemicals via Chirotech Ltd) have always had 
an interest in the use of biocatalysis for the production of chiral materials. 
Two examples will be given where hydrolytic enzymes have been used to 
produce useful chiral intermediates. The first of these involves the enzymic 
resolution of a bicyclic lactam 50 24 (Scheme 12). The single enantiomer lactam 
51 can then be converted into optically active carbocyclic nucleosides 
commonly used as anti-viral agents e.g.carbovir (Scheme 13). 
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Chiroscience developed two resolutions of this lactam. Firstly they used a 
whole cell system using a bacteria from Pseudomonas species. Here the cells 
were grown up by fermentation and the resulting biomass was frozen and 
stored. To carry out the resolution, all that was required was to add some of 
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the frozen cells to an aqueous solution of the racemic lactam. This gave the 
resolution products as shown in Scheme 12. An advantage of this process was 
that the fermentation was separate from the biotransformation so the 
organism could be grown, frozen, stored and used when required. Also the 
freeze-thaw process itself gave improved activity. This was because it caused 
some of the cells to break apart allowing some of the free enzyme to be 
liberated. 
The second resolution had the opposite stereoselectivity. In this case, 
Chiroscience were able to isolate and immobilise the lactamase enzyme from 
an Aureobacterium species. The resolution could then be simply achieved by 
cycling an aqueous solution of the racemate through a column containing the 
immobilised enzyme until the (-)-enantiomer was completely hydrolysed. The 
use of an immobilised system like this allows for large cost savings as the 
catalyst can be re-used many times. The downstream processing is also 
greatly simplified as there is no need to extract the resolution products from 
an aqueous medium containing the enzyme. Once the transformation is 
complete the aqueous reaction stream is poured into acetone. The 
unhydrolysed lactam remains in solution and the amino acid crystallises out 
and can be collected by filtration. 
The resolved lactam 51 may then be converted into the anti-viral agent 
carbovir 58 in ten steps. Firstly, the lactam is hydrolysed and then esterified to 
give the amino ester 53. To prevent the lactam from reforming, the amino 
group is acetylated by treatment with acetic anhydride. The ester is reduced 
with calcium borohydride to give the alcohol 55. After the removal of the acyl 
group by hydrolysis the free amine is coupled with 2-amino-4,6-
dichloropyrimidine to produce 56. Formation of the diazocompound by 







N H Ac 
Ac20 	'~J 








HO 9 ZeA NH2 







i) (EtO) 3 CH 
ii) NaOH NH2 
Carbovir 58 
Introduction 
with zinc in acetic acid affords the triamine 57. The guanine fragment is then 
formed by treatment with ethyl ortho-formate and then sodium hydroxide 
(Scheme 13). 
Ca(BH4)2  
ii) zinc, acetic acid 
Scheme 13 
Chiroscience have also developed other highly efficient enzyme catalysed 
resolutions. By combining their skills in enzyme isolation and immobilisation, 
with reactor design, they have come up with a cost effective and very 
stereoselective process for obtaining an enantiopure precursor to some 
important biologically active compounds. 
25 
hitrod iict im  
Chiroscience make use of another hydrolytic enzyme for their preparation of 
an unnatural amino acid L-BQC-TAZ 59 24  which is used as a mimic for a 
histidine residue in renin inhibitors. 
CO2H 
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After initial attempts using an esterase to selectively hydrolyse an ester 
intermediate had been unsatisfactory, they performed a resolution on the 
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Scheme 14 
The biotransformation forms part of a one-pot procedure starting from 
chloromethylthiazole and the acylase is able to carry out the resolution on a 
crude reaction mixture. 
This example illustrates that provided that the enzyme is sufficiently stable a 
biotransformation can be an integral part of a multi-step chemical sequence 
and there is often no need to isolate and purify the substrate prior to the 
bio transformation. 
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1.3.4 BASE 
BASF have been a major supplier of amines for many years. They consider 
amination reactions to be one of their core technologies. In 1993, they wished 
to develop the capability of producing optically pure amines. At the time 
lipases had been used extensively as acylation catalysts in the resolution of 
alcohols but there were very few examples in the literature of lipase catalysed 
resolutions of amines. BASF spent about one year carrying out screening 
experiments with 1-phenylethylamine as the substrate. 29 They looked at using 
different lipases and different acylating agents. The choice of acylating agent 
was crucial to the success of the resolution and it was found that the ethyl 
ester of methoxyacetic acid was an excellent acyl group donor for this 
resolution (Scheme 15). The selectivity factor, or E-value, was >1000. 
Interestingly, using ethyl butanoate the rate of acylation is much slower and 
the ee's of the resolution products are greatly reduced. This suggests that the 
methoxyacetyl group is more tightly bound possibly due to hydrogen 
bonding between the oxygen and amino acid residues close to the active site 
of the lipase. This would make a slight change to the geometry around the 
active site which may lower the activation energy required to form the second 
quaternary intermediate and hence increase the rate of the reaction. Also, the 
selectivity for the (R)-isomer may well be increased by a small change in the 









Using this enzymic resolution with a range of racemic amines, BASF were 
able to produce a wide range of optically active amines in quantities of greater 
than 100 t/a. They are currently developing this process in a dedicated plant 
with a view to producing chiral amines under strict cGMP guidelines by the 
end of 2001. 
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2.0 Aims of the Project 
The general aim for the project was to develop some novel routes for the 
synthesis of target chiral molecules using enzyme catalysis. Ultrafine were 
interested in biotransformations as it would give unique access to chiral 
molecules. Ultrafine were also aware that competitors were using enzymes 
for chiral synthesis and were keen to see if this type of technology would be 
appropriate for the synthesis of some of their chiral targets. 
Initially the project was planned to give a broad overview of biocatalysis and 
therefore to gain experience in the use of a range of different enzymes. The 
original plan was firstly, to use hydrolytic enzymes such as esterases and 
lipases for the kinetic resolution of appropriate substrates and then to move 
on to use other classes of enzymes such as reductases (both whole cell systems 
and isolated enzymes with co-factors). Although some time was spent looking 
at enantioselective reductions using Baker's yeast and isolated enzymes such 
as horse liver dehydrogenase, the majority of time for the project was spent 
studying the use of lipases in the kinetic resolution of chiral secondary 
alcohols. 
2.1 Preface to Chapter 3 
The first target molecule was bufuralol which is a beta-blocker and is sold by 
Ultrafine as the hydrochloride salt in the racemic form. Bufuralol is a 
substrate for a specific P450 isozyme and is part of a range of substrates, 
inhibitors, and metabolites available from Ultrafine. Chapter 3 describes an 
enzymatic route to optically enriched bufuralol. A lipase catalysed kinetic 
resolution of the precursor is the key step. 
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2.2 Preface to Chapter 4 
Methadone, the maintenance drug for heroin addicts, is generally prescribed 
as the racemic modification. The starting material in BockmUhl's original 
synthesis of methadone 30 is 1-dimethylamino-2-propanol and an efficient 
lipase catalysed resolution of this aminoalcohol is described in chapter 4. The 
conversion of the resolution products to enantiomerically pure methadones is 
described and the subsequent conversion of the less active d-methadone to 
levo-cc-acetyl methadol, a longer acting alternative to methadone, is also 
discussed. 
30 
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3.0 Results & Discussion I (Bufuralol) 
3.1 Introduction 
Bufuralol 60 was developed in the 1970's by Roche Products Limited as a 
adrenoreceptor blocking drug. 31 There are many examples of this class of 
drug and they have similar structures. They all contain an ethanolamine side 
chain and an aromatic ring. These can either be directly bonded as is the case 
for sotalol 61, or there can be an oxymethylene spacer separating the ring 
from the side chain e.g. propranolol 62. The structure of bufuralol combines 
both of these elements. The benzofuran ring is bonded directly to the 
ethanolamine side chain but also the side chain is separated from the benzene 
ring by the oxygen and C-2 carbon of the furan ring. 
Y~ 60 OH  NH'Bu 
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Bufuralol is a chiral molecule and the levorotatory (1'S) enantiomer is by far 
the more active isomer. 32 The dextrorotatory (1'R) enantiomer shows little or 
no activity in adrenergic assays. Bufuralol was resolved into its optical 
isomers by the Roche workers and this is described in their original 
publications.31' 33  They used a chiral acid 
- 
(+) and (-)-di-p-toluoyl tartaric acid 
- to form diastereomeric salts which were purified by crystallisation and then 
freed to give the optically pure enantiomers. The aim of our research was to 
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find an alternative route to (R) and (5)-bufuralol which used an enzyme 
catalysed transformation as the key step. 
The metabolism of bufuralol has been widely studied and approximately 
fifteen oxidative metabolites have been identified. Some of these have been 
shown to be potent f3-adrenoreceptor antagonists themselves and therefore 
contribute to the activity of the parent drug. 
Bufuralol is a good substrate for the single isozyme cytochrome P-450 11D6 
and this single enzyme has been the subject of much investigation. It is 
deficient or defective in 5-8% of the caucasian population. liltrafine supplies 
bufuralol as the racemic hydrochloride salt as part of their range of substrates, 
inhibitors, and metabolites for specific isozymes in the cytochrome P-450 
series. These compounds are sold worldwide as standards to medical research 
institutes. Ultrafine were interested in developing a route to (R) and (5)-
bufuralol as their clients had requested these for use as standard substrates in 
their metabolism studies. Also Ultrafine were interested in using 
biotransformations as this would allow them to develop a new technology in 
house which may well prove useful for other synthetic targets. 
3.2 Approaches to Bufuralol 
The synthesis of bufuralol was first published as a communication in 1975 33 
by workers at Roche Products Limited and this was later followed by a full 
paper in 1977.' These reports give details of an eight step synthesis starting 
from 2-ethyiphenol 63 blocked in the para position with a bromine atom 
(Scheme 1). The bromine substituent was necessary in order to direct mono-
formylation to the ortho- position of the phenol 63 in the first step and was 
readily removed in the final step by hydrogenation. Cyclisation of the 
salicylaldehyde 64 was effected by ether formation with chloroacetone and 
ring closure under basic conditions. The methyl ketone 65 produced was 
chlorinated by reaction with sulphuryl chloride and then reduced with 
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sodium borohydride to the chlorohydrin 67. Base treatment gave the epoxide 
68 which was reacted with tert-butylamine to give the bromo-protected 
bufuralol 69. Some of the primary ethanolamine was also formed due to tert-
butylamine attack at the more hindered end of the epoxide 68. It was reported 
that the presence of the bromine substituent on the benzofuran ring 
suppressed the formation of this unwanted isomer. The final step was the 
removal of this bromo group by hydrogenation at atmospheric pressure to 
give bufuralol 60. 
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This route to bufuralol, developed at Roche, has several low yielding steps 
and the overall yield for the process is 4%. An improved synthesis was 
published in 1991 by Nelson et al.34 These workers initially described a 
twelve step synthesis starting from 63 with an overall yield of 10%.  They go 
on to give details of a more efficient shorter route (Scheme 2). The starting 
material and the first step are as described by the Roche workers, but Nelson 
et al. claim a higher yield of 61% (Roche 31 - 54%). The salicylaldehyde 64 can 
then react with bromoacetaldehyde diethyl acetal in DMF in the presence of 
potassium carbonate to give the O-alkylated product 70. Cyclisation to give 
the benzofuran 71 is achieved by acid catalysed intramolecular aldol 
condensation. Methylene transfer using dimethylsulphonium methylide in 
tetrahydrofuran - dimethylsulphoxide affords the epoxide 68. The epoxide is 
then opened by reaction with tert-butylamine and the bromine removed by 
hydrogenolysis following the same procedure as the Roche workers. 
34 
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3.3 Resolution of Bufuralol 
As mentioned in the introduction to this chapter, bufuralol has been 
classically resolved into its optical isomers by the formation and 
crystallisation of diastereomeric salts using (+) and (-)-di-p-toluoyl tartaric 
acid. Our initial work centred on the use of a lipase mediated kinetic 
resolution in an attempt to resolve bufuralol itself. An initial experiment was 
carried out using Lipase PS (Pseudornonas cepacia) and vinyl acetate as acyl 
donor. The conditions were based on those used by Schneider et al / 35 in their 
resolution of 2-phenylethanol. Unfortunately no ester formation was observed 
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and only racemic bufuralol was recovered from the reaction. This was 
probably due to the bulky tert-butyl group preventing access to the active site 
of the lipase. 
3.4 Preparation of the chioroalcohol 80 
There was literature precedence for lipase resolution of the chloroalcohol 
precursor as other 3-adrenoreceptor antagonists have been prepared as 
optical enantiomers using this methodology. 36Candida antarctica lipase type B 
was used for the resolution of the 1-aryloxy-3-chloro-propan-2-ol precursors 
to four beta-blockers. The resolutions were carried out both by 
hydrolysis/alcoholysis of the 0-acetate derivatives and by acylation of the 
racemic alcohols using vinyl acetate as the acyl donor. The precursor to 
propranolol was efficiently resolved by Candida antarctica catalysed hydrolysis 
of the 0-acetate derivative both the alcohol and unhydrolysed ester were 
obtained with 95% ee. Thus the chloroalcohol 80 became the first target 
molecule to try some lipase catalysed resolutions. The route chosen to 
generate the chloroalcohol 80 (Scheme 3) was similar to Ultrafines published 
synthesis of hydroxybufuralol - a metabolite. 37 
Starting with 2-ethylphenol 73, the allyl ether 74 is formed in good yield by 
reaction with allyl bromide in the presence of potassium carbonate. Claisen 
rearrangement of this allyl ether has been reported as giving a 9:1 ratio of 
ortho:para products. The minor para regioisomer was observed in the NMR 
spectrum, the doublet signal from the methylene of the allyl group in the para 
product is shifted upfield by O.ilppm compared to that of the major, 2-allyl-6-
ethylphenol 75. The relative amounts of these two regioisomers were not 
quantified and they were not separated, simply reacted through the next step 
as a mixture. Palladium catalysed rearrangement of the double bond gave the 
styrene 76 as a mixture of cis and trans-isomers which could be seen in the 
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220MHz NMR spectrum. The key signal is the doublet of the methyl group 
which in the minor cis-isomer is shifted upfield by 0.19ppm. Oxidative 
cleavage of the double bond gave the benzaldehyde 77. It was found that 
using osmium tetroxide and sodium periodate gave the best yield but 
ruthenium trichloride and sodium periodate were also tried in a two-phase 
system with less success. Low temperature ozonolysis has been used before 
by Ultrafine and this gives similar yields but specialist equipment is required 
and this has always been carried out off site and so is less convenient. The 
benzaldehyde 77 was purified by chromatography. 
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The next step is the condensation of the benzaldehyde 77 with chioroacetone 
to give the benzofuranyl methyl ketone 78. Similar conditions to those used 
by the Roche workers were employed but potassium carbonate was used as 
the base instead of potassium hydroxide because use of the stronger base was 
reported 38  to give rise to a byproduct - the 2,2'-hydroxycinnamoylbenzofuran 
derivative 72 which we did not observe using potassium carbonate. 
Attempts to form the chioromethyl ketone 79 directly by using 
dichioroacetone were unsuccessful. In Ultrafines preparation of 
hydroxybufuralol the equivalent intermediate at this stage has a methyl 
ketone replacing the ethyl group at the 7-position and this compound reacts 
with dichloroacetone in the presence of a suitable base to give the 
chlorodiketone albeit in low yield and with the bis-benzofuranyl ketone as a 
significant side product. Why no reaction at all occurs in the bufuralol series is 
somewhat of a mystery. 
The Roche workers report 31  that the chlorination of the methyl benzofuranyl 
ketone proceeds smoothly by reaction with sulphuryl chloride in refluxing 
chloroform solution. We found that using these conditions for our substrate 
gave no sign of any product so a few drops of 2M hydrochloric acid were 
added. The reaction then proceeded and produced a mixture of mono and 
dichlorinated methyl ketones and it was difficult to control the reaction to 
stop at the monochlorinated stage. The monochlorinated product 79 was 
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prepared by firstly trapping the enol tautomer of the ketone as the silyl enol 
by reaction with triethylamine and trimethylsilyl triflate and then reacting 
with N-chlorosuccinimide. Under these conditions only the monochiorinated 
ketone 79 was produced but in only 23% yield. 
Reduction of the chloroketone 79 with sodium borohydride in ethanol 
produced the desired chloroalcohol 80 in quantitative yield. It was now 
possible to investigate some lipase resolutions of this substrate. 
3.5 Lipase catalysed resolutions of the chioroalcohol 80 and conversion of 
the resolution products to bufuralol 
The chioroalcohol precursor to bufuralol 80 was subjected to 
transesterification using trifluoroethyl octanoate as the acyl donor and four 
different lipases obtained from Amano were used (Scheme 4). The 
trifluoroethyl octanoate was prepared by the reaction of trifluoroethanol with 
octanoyl chloride in pyridine with a catalytic amount of DMAP. In all four 
cases there was tic evidence of ester formation. The Candida sp. lipase gave the 
greatest yield of octanoate ester 81 - 19 %. A tiny amount of product was also 
isolated from the Pseudoinonas sp. lipase reaction - 1%. The optical purities of 
these isolated esters was determined by shift reagent NMR spectroscopy 
using a chiral europium reagent - Eu(l fc)3 39 . A racemic sample of the 
octanoate ester 81 was firstly prepared by the reaction of octanoyl chloride 
with the chioroalcohol 80 in pyridine with DMAP as catalyst and the racemic 
ester was analysed by chiral shift NMR spectroscopy. The singlet from the 
proton at C-3 of the furan ring - 66.8 starts to split into two signals as chiral 
shift reagent is added. Unfortunately, as more shift reagent was added, 
baseline separation of these two signals was not observed before they started 
to coalesce with the other aromatic signals. 
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Chiral shift analysis of the octanoate ester Si produced from the Lipase AY 
catalysed transesterification shows two unequal signals for the C-3 proton but 
they are not completely resolved. However, an approximate cc of 75% can be 
obtained from the relative integrals of these peaks. Analysis of the small 
amount of ester obtained from the Lipase PS (Pseudomonas) catalysed reaction 
showed only one peak after treatment with chiral shift reagent. So, although 
this lipase gives a very poor yield for the resolution, it is very selective and 
gives optically pure product. This early positive result was very encouraging 
and led us to further investigations using both Lipase AY and Lipase PS 
aiming to increase the selectivity and yield respectively. 
Vinyl acetate is a widely used acylating agent for lipase catalysed 
transesterifications. 40  This is due to the fact that the reaction is irreversible as 
the byproduct is acetaldehyde which is a gas and is lost to atmosphere. (This 
is convenient on a small scale but may cause problems on a large scale as 
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acetaldehyde is very toxic and would need to be contained.) The resolution of 
the chloroalcohol 80 was attempted using vinyl acetate and Lipase AY with 
vinyl acetate also acting as the solvent. Some of the literature examples have 
vinyl acetate as both solvent and acyl donor and others try a range of solvents 
and show that choice of solvent is important for both selectivity and yield. It 
may be useful for future work to optimise this resolution by investigating a 
range of different solvents. The mixture was stirred gently for 48h and the 
resolution products were separated by chromatography. The acetate ester (5)-
82 obtained in 18% yield was hydrolysed back to the alcohol (S)-80 by Lipase 
AY catalysed hydrolysis. The lipase was used in both modes - for 
esterification and hydrolysis to optimise the optical purity of the product and 
the resolved (5)-alcohol (S)-80 was thus obtained in overall yield of 29% 
(Scheme 5). The enantiomeric excess of the alcohol was not measured at this 
stage - the material was further reacted to bufuralol itself using the same 
procedure used for the preparation of hydroxybufuralol. 34 Potassium 
carbonate, tert-butylamine and a catalytic amount of potassium iodide were 
added to a solution of the (5)-alcohol (5)-52 in DMF and the mixture was 
heated at reflux for 7 hours. (R)-Bufuralol (R)-32 was isolated in 47% yield as a 
yellow oil with an enantiomeric excess of 50% as determined by chiral FIPLC. 
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The same resolution strategy was employed using Lipase PS and vinyl 
acetate. Again the enzyme was used for both esterification and hydrolysis. 
(Scheme 6) The (5)-alcohol (5)-80 was obtained in 44% overall yield from the 
racemic alcohol SO and was reacted through to (R)-bufuralol (R)-60. Lipase PS 
gave (R)-bufuralol (R)-60 with an ee of 90%  as determined by chiral HPLC. 
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3.6 Conclusions and Suggestions for Future Work 
A novel route to optically enriched bufuralol has been described. The key step 
used to introduce the chirality is a lipase mediated kinetic resolution of the 
precursor, the chloroalcohol 80. (R)-Bufuralol (R)-60 was obtained with cc of 
90% but in low yield. The resolution is the penultimate step in the synthetic 
sequence and it is expensive to lose at least half the weight at this stage. A 
better strategy would be to have the resolution as early in the synthesis as 
possible or alternatively to racemise the undesired isomer and repeat the 
resolution. This can sometimes be done in one pot and this is known as 
dynamic resolution 41  and the theoretical maximum yield doubles to 100%. 
This is certainly worth considering as an area for future work. 
The route to the substrate for the resolution has several low yielding steps and 
there is certainly room for improvement. On going work at Ultrafine is 
looking at the direct orthoformylation of 2-ethylphenol 73•42  This would cut 
the first four steps to one step and would also avoid the low yielding 
oxidative cleavage of the styrene 76. 
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4.0 Results & Discussion II (Methadone) 
4.1 Introduction 
Methadone, or Amidone as it was originally named, was first prepared by I.G. 
Farbenindustrie workers at Hoechst-am-Main in Germany during the Second 
World War. 30 It was developed as an analgesic with an activity similar to that 
of morphine. In fact methadone 83 is an open chain analogue of morphine 84 
and obeys the 'morphine rule'. 43 i.e. :- 
It has a tertiary nitrogen with a small alkyl substituent 
It has a quaternary carbon 
It has a phenyl group bonded to the quaternary carbon 
There is a two carbon spacer between the quaternary carbon and the 
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Figure 1 
Methadone is still a prescribed drug on the market today and is mostly used 
in the long term maintenance of heroin addicts. Heroin is the 3,6-diacetyl 
derivative of morphine and is 2-3 times more potent. Most of this increase in 
potency is due to its greater lipophilicity which leads to rapid CNS 
penetration. Methadone acts as a slow release heroin mimic. It accumulates in 
the lipid tissue outside of the CNS and has a slow onset and long duration of 
action.43 So although methadone does not give the same initial feeling of 
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euphoria as heroin it can be effective in reducing an addict's craving and 
therefore use of heroin. 
Recently there has been some interest in the use of methadone in the 
treatment of cancer pain. 44 Workers at the Pain Research Institute in Liverpool 
have shown that methadone can be particularly effective for the management 
of cancer pain for those patients who respond poorly to morphine based pain 
relief. 
4.2 Literature routes to homochiral methadones 
4.2.1 Classical resolution chemistry 
Methadone, 6-dimethylamino-4,4-diphenyl-3-heptanone has one asymmetric 
carbon at C-6. The biologically active isomer is levomethadone. Several 
workers in the late 1940's reported resolutions of methadone into its optical 
isomers.45-48 Brode and Hill 45  reported that methadone formed 
diastereomeric salts with D-tartaric acid and that these could be separated 
and freed to give pure 1-methadone and d-rich methadone. The d-rich 
methadone was further purified by melting, the pure d-isomer has a higher 
melting point to the eutectic mixture of d and 1-isomers. Larsen et al ,46  also 
used D-tartaric acid as their resolving agent but they also studied the 
resolutions of isomethadone 85 and the two nitrile precursors 86 and 87 
(Figure 2). They stated that all four compounds were readily resolved into 
their optical isomers. However, a closer inspection of the experimental details 
reveals that the method for the resolution of the nitrile compounds is far 
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This is further corroborated in a report by Walton, Ofner, and Thorp 47  in 
which they comment that 'The resolution of methadone was attempted by 
means of a variety of optically active acids but without marked success" and 
also that "The penultimate cyanide, on the other hand was readily resolved by 
means of D-tartaric acid." Howe and Sletzinger 48  used more exotic resolving 
agents in their resolutions of methadone and isomethadone. They found that 
d-methadone formed an insoluble d-a-bromocamphor-it-sulphonate and that 
1-methadone could be obtained from the mother liquors. This was achieved by 
neutralising, forming the d-tartrate salt and allowing this to crystallise from 
an n-butanol solution. The 1-methadone-d-tartrate was then directly converted 
to the hydrochloride by succesive treatment with sodium hydroxide then 
hydrochloric acid. These workers also used p-nitrobenzoyl-L-glutamic acid for 
the resolution of isomethadone. 
4.2.2 Synthesis from 'Chiral Pool' starting material 
In a study of the stereochemistry of the synthesis of methadone, 49 Barnett and 
Smirz obtained their chiral starting material (S)-(+)-1-dimethylamino-2-
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They then essentially followed the procedure of Bockmuhl and Erhardt 30  to 
give the optically pure nitrile precursor to methadone in two steps 
(Scheme 2). 
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Scheme 2 
The (S)-aminoalcohol (S)-89 was treated with thionyl chloride in chloroform 
and the mixture heated to reflux. The reaction proceeded with inversion of the 
stereocentre to give 1-dimethylamino-2-chloropropane (R)-90 as the 
hydrochloride salt. This was converted to the free base and then treated with 
sodium diphenylacetonitrile in toluene which gave a mixture of the two 
regioisomeric nitriles. The desired aminonitrile (S)-86 was isolated by 
chromatography. These workers do not describe the final step which would 
give chiral methadone but this could simply be achieved by Grignard reaction 
with ethylmagnesium bromide followed by acid hydrolysis as in the original 
procedure. 30 
4.3 A new lipase mediated approach to the synthesis of 1-methadone 
Although the activity of methadone is attributed to the levo-isomer it is 
generally prescribed as the racemate. The main reason for this is that the 
currently available methods (described in 4.2 above) are either impractical or 
too costly, or both. Resolution at the nitrile stage or on the final product itself 
(4.2.1) is particularly inefficient as this involves the loss of at least half of what 
is relatively expensive material. A much better approach would be to resolve 
the cheap starting material at the beginning of the synthesis. The racemic 
aminoalcohol 89 looked as though it would be a good substrate for a lipase 
catalysed resolution by transesterification as there is a reasonable difference in 
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the size of the two groups attached to the chiral centre. Provided that the 
selectivity is high this would give access to both optical isomers of the 
aminoalcohol 89 and hence a route to both d and 1-methadones. 
The initial resolution of 1-dimethylamino-2-propanol 89 was carried out on a 
small scale using Lipase PS (Amano) as the biocatalyst. The relative amount of 
enzyme preparation to substrate was 1:4 w/w and the acyl donor and solvent 
was vinyl acetate. The reaction mixture was allowed to stir at ambient 
temperature for two days and then the lipase was removed by filtration. 
0 
( 	Me2N Me2 N 	 Me2 N ' 
OH 	Lipase PS 	 O- OH 
89 	 (R)-91 0 	(S)-89 
Scheme 3 
The acetate ester (R)-91 was isolated by chromatography and analysed for 
optical purity by chiral shift reagent NMR spectroscopy using a chiral 
europium complex - Eu(hfc)3 39. The shift reagent NMR spectrum for the 
racemic ester gave two equal peaks for the acetate signals. So the relative 
integrals of these peaks in the NMR spectrum of the resolved ester gave a 
value for the enantiomeric excess of the compound (Figure 3) 
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Figure 3 Chiral shift NMR spectra for the racemic acetate 91 and the resolved 
acetate (R)-91. 
This first resolution gave a conversion of 60% and the ester (R)-91 had an ee of 
46%. Thus Lipase PS shows only moderate selectivity in this resolution. The 
optical purity of the product ester could be improved by removing the lipase 
after only 16 hours reaction time. This gave a conversion of 33% but the 
acetate ester (R)-91 was obtained with an ee of 88%. (Figure 4) 
• 	 •. 	 - 	 - 	 - 
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Figure 4 Chiral shift NMR spectrum for the resolved acetate (R)-91 at 33% 
conversion 
It is often the case, in lipase catalysed transesterifications, that the optical 
purity of the ester can be improved by stopping the reaction at less than 50% 
conversion. Conversely, the optical purity of the remaining alcohol can be 
optimised by pushing the resolution to beyond 50% conversion. 
Unfortunately, for these initial resolutions, we were unable to isolate the 
unreacted alcohol (S)-89 from the chromatography column. Even eluting with 
1:1 methanol: dichloromethane was not sufficient to recover the polar amino 
alcohol from the column. 
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Having achieved some selectivity using Lipase PS from Amano, it was now 
important to try other lipases to hopefully improve the selectivity. Novo 
Nordisk AS generously provided a sample of their Novozyme ® 435. This is 
an immobilised preparation of Candida antarctica lipase type B often 
abbreviated to CALB. There are many examples in the literature where this 
lipase has been used very effectively in resolution chemistry. 51-53 It was also 
important to find an alternative to chromatography for isolating the 
resolution products. As we were unable to isolate the remaining amino 
alcohol and chromatography would make scale up very difficult. 
It was found that using Novozyme ® 435 and vinyl propanoate as the acyl 
donor (Scheme 2) the resolution products could be conveniently separated by 
firstly filtering off the lipase and washing thoroughly with ethyl acetate and 
then by washing out the water soluble 1-dimethylamino-2-propanol (S)-89 
with several portions of water. The ethyl acetate layer was then dried and 
evaporated to leave the propanoate ester (R)-92 as a yellow oil in 35% yield by 
weight (optimum yield 50%). 
Me2 N 	 Me2 N 	 + Me2 N 
OH Novozyme ® 435 	 OH 
89 	 (R)-92 o 	(S)-89 
Scheme 4 
Several attempts were made to extract the resolved alcohol (S)-89 from the 
water layer using many organic solvents but without success so again we 
were unable to isolate the alcohol. The optical purity of the propanoate ester 
(R)-92 was not measured as chiral shift reagent NMR spectroscopy was 
unsuitable for the higher ester. The signals which were split by the europium 
reagent were multiplets and as more shift reagent was added it was 
impossible to obtain baseline separation before the signals broadened out and/ 
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collapsed. Alternative methods for chiral analysis were developed later (4.5) 
but at this stage the material was reacted through to the 1-dimethylamino-2-
chloropropane (S)-90 for which there was a literature value for its optical 
rotation 49  (Scheme 5). The ester (R)-92 was firstly hydrolysed back to the 
alcohol (R)-89 by a Zemplen type methanolysis 54  using a catalytic amount of 
freshly prepared sodium methoxide in methanol and then treated with 
thionyl chloride in chloroform and heated to reflux to give (S)-(+)-1-
dimethylamino-2-chloropropane (S)-90 as the hydrochloride salt. 49 
Me2N( 	NaOMe Me2N( 




CHCI3 reflux 	HCI 61 
(S)-90 
The optical rotation was measured after one recrystallisation from 2-propanol 
- [aID = +59.10 (c 2.075, H20). This compares to the literature value of -65° 
(c 2.01, H20) for the (R)-(-)-isomer. 49 A further two recrystallisations from 
2-propanol gave material with [alo = +65.9° (c 2.01, H20). At this stage we 
had obtained the opposite enantiomer to that which Barnett and Smirz 49  used 
in their study examining the stereochemistry of the methadone synthesis. We 
assumed that these workers were working with precursors to the biologically 
active levomethadone. So we wished to isolate the unreacted (5)-alcohol 
(S)-89 from the resolution as we believed this to be the starting material for 
1-methadone. It was also necessary to obtain some chiral analysis for the 
resolution products. 
The resolution of 1-dimethylamino-2-propanol 59 was again carried out using 
Novozyme ® 435 and vinyl propanoate as the acyl donor. The conditions 
were varied slightly so as to push the resolution to beyond 50% conversion in 
an attempt to give the required (5)-alcohol (S)-89 with higher optical purity. 
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The reaction was stirred slowly at 40°C for 3 days and a small excess of vinyl 
propanoate was used - 0.6 equivalents. The (5)-alcohol (S)-89 was isolated by 
distillation at reduced pressure and was obtained as a colourless oil in 32% 
yield based on a maximum desired yield of 50%. The second component to 
distil was the (R)-propanoate ester (R)-92 which distilled at 60°C at 
approximately 5mm Hg pressure and was obtained as a colourless oil in 36% 
yield. The optical rotation of the (5)-alcohol (S)-89 was measured in ethanol, 
Lab = +23 0 and this compared very well to the literature value of +24 0 . The 
(5)-alcohol was then converted through to homochiral methadone (Scheme 6). 
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Scheme 6 
The (R)-l-dimethylamino-2-chloropropane (R)-90 was formed as the 
hydrochloride salt by the reaction of the alcohol (S)-89 with thionyl chloride 
in chloroform. This compound was then recrystallised from 2-propanol to 
give material with an optical rotation comparable to that given in the 
literature. 49  The chloro compound (R)-90 was then added to a rapidly stirred 
mixture of diphenylacetonitrile in aqueous sodium hydroxide/ 
dimethylsulphoxide with a catalytic amount of dibenzo-18-crown-6 55 The 
desired nitrile (S)-86 was obtained in low yield (33%). The mechanism for this 
step is thought to go via an aziridinium ion intermediate (Scheme 7). 
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As shown the diphenylacetonitrile anion can attack this reactive intermediate 
at two sites giving rise to two isomeric products. The desired product (S)-86 is 
favoured as this results from attack at the less hindered centre. The 18-crown-
6 acts as a phase transfer catalyst which allows the reaction to be carried out 
at a lower temperature and favours formation of the desired aminonitrile 
(S)-86. This reaction was studied by Poupaert et cii. 55  and using these 
conditions they observed a 72:28 ratio in favour of the desired isomer (S)-86 
using direct CC analysis of the reaction mixture, and they isolated the desired 
product in 44% yield. In our hands, the aminonitrile derivative (S)-86 was 
isolated by crystallisation from hexane in 33% yield and no attempt was made 
to isolate the unwanted isomer (S)-87. The optical rotation was measured as 
[a]0 = +52.90  which compares to +49° in the report by Barnett and Smirz. 49 
Conversion of the nitrile compound (S)-86 through to methadone was 
achieved by Grignard attack at the nitrile carbon followed by hydrolysis to 
give the ketone (S)-83 in 53%  yield. This was the same procedure as that used 
by Bockmuhl and Erhardt. 30 The optical rotation was measured and found to 
be [ulo = +1360 . So by following the publication of Barnet and Smirz, 49 the 
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inactive dextro rotatory isomer of methadone (S)-83 had been produced. It 
was wrong to assume that their report was based on the precursors to the 
active levomethadone. 
The (S)-(+)-1-dimethylamino-2-chloropropane (S)-90 had already been 
prepared from the ester (R)-92 isolated from the resolution. So to obtain the 
active 1-methadone it was simply a matter of repeating the final two steps 
described above. 1-Methadone was obtained as the hydrochloride salt 
([ctIID = - 1360 ) in a comparable yield to its optical antipode. 
4.4 Chiral HPLC analysis 
Having obtained both d and 1-methadones in high optical purity as 
demonstrated by their [cxj0 values we wished to explore a possible chiral 
HPLC method in order to obtain enantiomeric excess values for both optical 
isomers. Kristensen et al. 56  published a method for the determination of the 
enantiomers of methadone in blood serum using a chiral HPLC column from 
Chromtech. Using this column we were able to demonstrate that the 
enantiomers of methadone had different retention times. By testing a racemic 
sample obtained from Sigma using a mobile phase of 840:160 0.01M sodium 
phosphate buffer at pH 6.5: acetonitrile and a flow rate of 0.9m1/min two 
peaks were observed of equal intensity at just over 10 mins and 13.1 mins. 
According to the Danish workers the first compound to elute was 
(R)- (-)-methadonefollowed by (S)-(+)-methadone. On analysing the chiral 
methadones we had synthesised this was found to be the case and in both the 
HPLC traces no evidence for the presence of the opposite enantiomer was 
observed. So essentially using an enzymatic resolution of the starting amino 
alcohol optically pure (R) +)-methadoneand (S)-(+)-methadone have been 
prepared. The ee values are quoted as >99% because of the limit of detection 
of the HPLC instrument. 
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4.5 Chiral CC analysis of the resolution products 
The optical purity of the methadones had been established yet there was still 
limited analytical data for the products of the resolution. So the resolution of 
1-dimethylamino-2-propanol (S)-89 was carried out again and the reaction 
mixture was analysed periodically by chiral CC using a 13-cyclodextrin 
column. The racemic 1-dimethyktmino-2-pi -opyl propanoate 92 was firstly 
prepared by the reaction of the racemic aminoalcohol 89 with propanoyl 
chloride. The ester isolated from this reaction was resolved into an even 
doublet by the CC column. Chiral CC analysis of the resolution reaction 
mixture after 2h showed that the conversion of aminoalcohol 89 to the 
propanoate ester (R)-92 was already 19% and the minor (S)-propanoate ester 
can only be seen as a tiny blip on the CC trace and was not integrated 
(Figure 5). Thus, an accurate ee value cannot be quoted but it can be assumed 







Racemate 	 Reaction time - 2h 
Figure 5 Chiral CC trace for the racemic propanoate ester 92 and for the 
resolution reaction mixture after 2h 
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After 4h the conversion was 32% and the ee of the propanoate ester (R)-92 
was 95.9%. Further samples were taken at 16, 17, and 18 h and the results are 
represented in the graph below. 
Figure 6. The resolution of 1-dimethylamino-2-propanol 89 using 
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A final sample was analysed after a reaction time of 88h and this showed that 
the resolution was complete at 50% conversion and that the ee of the product 
ester was still high at 95.6%. Thus the Novozyme ® 435 lipase preparation is 
extremely selective in this resolution. It is almost specific for the (R)-
aminoalcohol (R)-89 and even after over 3.5 days reaction time only a very 
small amount of (S)-ester (S)-92 was detected. 
4.6 Lipase screen 
Having found a good method of analysis which gives both the degree of 
conversion to the ester and the ee of the ester and having obtained a 
chirazyme® lipase screening kit as a gift from Boehringer Mannheim it was 
now possible to carry out a screen using the substrate 1-dimethylamino-2-
propanol 89 and the various enzyme preparations in the kit (Table 1). 
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Li Burkho/deria sp. 
L2 Candida antarctica, fraction B 
L3 Candida rugosa 
L4 Pseudomonas sp. 
L5 Candida antarctica, fraction A 
L6 Pseudomonas sp. 
L7 Porcine pancreas 
L8 Hurnicola sp. 
Table 2. Results of the resolution of 1-dimethylamino-2-propanol 89 using the 
chirazyme® screening kit 
Entry 	Lipase 	Time/h 	Conversion/% 	ee/% 
1 Li 2 6 
2 Li 21 66 
3 L2 2 0 
4 L2 21 2 
5 L3 2 0 
6 L3 21 2 
7 L4 2 37 
8 L4 70 95 
9 L5 2 0.5 
10 L5 70 48 
ii L6 2 2 
12 L6 70 87 
13 L7 2 3 
14 L7 70 45 
15 L8 2 0 
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It can be seen from the results given in Table 2 that most of the lipases showed 
some activity. In fact, only lipase L-8 gave no reaction at all and no product 
ester was observed in the CC trace. Lipases L-1, L-4, and L-6 showed good ee 
values for the product ester after short reaction times but after prolonged 
reaction the percentage conversion increased to beyond 50% and hence the 
selectivity fell. Lipases L-1 and L-2 gave slow rates for the resolution but L-2 
showed a high selectivity. Out of all the lipases in the kit L-7 was the most 
promising (entries 13 and 14), initially showing very high selectivity and after 
70 hours gave the ester with an ee of 80.3% and a degree of conversion of 45%. 
Curiously, lipase L-5 showed a reasonably strong preference for the (S)-
aminoalcohol and after 3 days (entry 10) gave the (5)-propanoate ester (S)-92 
with an cc of 58.1%. 
4.7 Large scale resolution 
The lipase screen has shown that none of the lipases in the Chirazyme ® kit 
are as effective as Novozyme ® 435 for the resolution of 1-dimethylamino-2-
propanol 89 with vinyl propanoate as the acyl donor. Thus the resolution was 
scaled up using Novozyme ® 435 to establish whether or not the same 
methodology was appropriate for a kilogram scale transesterification. 
1 Kg of the aminoalcohol 89 was treated with vinyl propanoate (0.5 
equivalents) and 3% by weight Novozyme ® 435 was added. The mixture 
was stirred for three days and the resolution products were both isolated by 
distillation at reduced pressure. The unreacted (S)-aminoalcohol (S)-89 was 
the first compound to distill and was obtained as a colourless oil in 45% yield. 
This compares to a yield of 32% when the same resolution was carried out on 
a small scale. The (R)-propanoate ester (R)-92 distilled over as a colourless oil 
in 36% yield and again this is slightly higher than that obtained from the 
small scale resolution. An overall recovery of 81% was obtained for this large 
scale resolution. The resolution products were reacted through to the optical 
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isomers of methadone (R)-83 and (S)-83 using the same procedure as for the 
small scale syntheses. 94g of 1-methadone hydrochloride (R)-83 were obtained 
with an cc of 88.6%. 
4.8 Levo-ct-acetylmethadol 
4.8.1 Introduction 
Methadone was just one of a series of compounds which were studied as part 
of the research activities of I.G. Farbenindustrie at Hoechst-am-Main in 
Germany during the Second World War 30.  Workers in America in the mid to 
late 1940's also produced a wide variety of related compounds. 47 One of these, 
the acetoxy derivative had a similar potency to methadone. It was prepared 
by several groups in 1948 and 1949. Firstly, in 1948, May and Mosettig 57 
reported that amidone (methadone) could be reduced by hydrogenation with 
platinum oxide (Adam's catalyst) to give the carbinol and that only one of the 
two possible pairs of diastereoisomers were obtained - the ci-methadols 
(Scheme 8). 
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Scheme 8 
A possible explanation for this is that methadone is held in a five-membered 
ring due to the attraction of the lone pair of electrons on the nitrogen to the 
carbon of the carbonyl group (Figure 7). Due to the free rotation of the bond 
between the quaternary carbon and the carbonyl carbon two conformations 
are possible. The 1,3-interaction between the methyl and ethyl groups is 
minimised when they are trans to each other and therefore this is the lowest 
energy conformation. Therefore (5)-methadone is reduced to (25, 55)-
methadol and (R)-methadone gives (2R, 5R)-methadol. 
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Figure 7 
May and Mosettig reported that acetylation of the methadol could be 
achieved by reaction with acetic anhydride in pyridine but this was low 
yielding. Better yields were obtained by firstly deprotonating with ethyl 
magnesium bromide and then reaction with acetic anhydride. This gave the 
0-acetyl derivative 93 in 80-90% yield. Pohland et al at the Lilly Research 
Laboratories, USA reported 58  the synthesis of the 0-acetyl derivative and also 
included some preliminary pharmacology tests carried out on the rat. These 
showed that although the cc-methadols showed little activity compared to 
methadone, the a-acetyl methadols had similar activities. The d-isomer 
derived from the active 1-methadone had double the activity of racemic 
methadone. The 1-isomer 93 derived from d-methadone had a lower analgesic 
activity (5.4 times lower than the d-isomer) but had a delayed onset and a 
long duration of action. 59 It is these properties which make the 1-isomer a 
useful alternative to methadone in the maintenance of heroin addicts. 
61 
Results and Discussion I! 
In the U.S., LAAM has been shown to be effective in maintenance programs 
when it is administered three times a week 60  whereas methadone needs to be 
taken every day. As patients taking LAAM spend less time in the clinic they 
may have more normal lifestyles and may be able to find employment. This 
would obviously help in the rehabilitation of the patient and offers a 
significant advantage over methadone. 
4.8.2 The synthesis of LAAM from d-methadone 
d-Methadone (S)-83 was obtained from (S)-(+)-1-dimethylamino-2-propanol 
(S)-89 in three steps, having isolated the homochiral aminoalcohol from a 
lipase mediated transesterification of the racemic material as described earlier 
(4.3). An initial attempt to reduce d-methadone was made using the 
conditions described by May and Mosettig in their original publication. 57 
Thus, d-methadone was hydrogenated in a Parr hydrogenation apparatus 
with platinum (IV) oxide as the catalyst. After overnight reaction, the product 
was isolated and found to be a mixture of methadone and the reduced 
methadol 94. The reduction of d-methadone was also tried using sodium 
borohydride as the reducing agent with a catalytic amount of the Lewis 
acceptor cerium (III) chloride and this proceeded very smoothly and the 
reduced methadol 94 was obtained in quantitative yield. As the borohydride 
reduction was so successful no further attempt was made to push the 
hydrogenation to completion. Conversion of the methadol 94 obtained to the 
acetate ester 93 was simply achieved by treatment with acetyl chloride and 
heating to reflux in ethyl acetate (Scheme 9). 
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LAAM 93 was isolated as the hydrochloride salt in 84% yield. The [aID was 
measured as -60.6° which is slightly higher than the value quoted in the 
literature of 59°58  Thus, using a slightly modified route (from that used by 
May and Mosettig) LAAM has been obtained in excellent yield and high 
optical purity based on its optical rotation. 
4.9 Conclusions and suggestions for future work 
A lipase catalysed resolution of 1-dimethylamino-2-propanol 89 has been 
described which is highly stereospecific. The resolution products have been 
reacted through to the enantiomerically pure isomers of methadone and the 
process has been scaled up. The initial resolution can be carried out using 1Kg 
of substrate aminoalcohol 89 which gives approximately lOOg of the active 
1-methadone (R)-83 and further scale up to pilot plant and even larger would 
present few difficulties. The d-isomer (S)-83 has been converted in two steps 
to levo-(x-acetylmethadol 93 which is prescribed as a longer acting alternative 
to methadone to heroin users in the U.S. 
The possibilities for further work are quite considerable:- 
i) The scope of the resolution itself could be studied. In particular, the effect of 
the presence (or absence) of the tertiary amine group in the substrate molecule 
on the selectivity and conversion rate could prove to be an interesting area of 
research. Several groups including our own 41  have used nitrogen bases such 
as triethylamine or pyridine as additives in similar kinetic resolutions and in 
some cases they have a marked effect. The reason for this is a matter of some 
speculation but they are thought to prevent the inhibition of the enzyme by 
coordinating to any polar substances which may be present and which may 
otherwise coordinate to the amide bonds in the lipase and affect the activity of 
the catalyst. This topic has been recently reviewed by Theil. 61 
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Another area which could be suitable for further work is the use of 
alternative carbanions other than that of diphenylacetonitrile to attack the 
intermediate aziridinium ion which is the proposed intermediate formed in 
the penultimate step of the methadone synthesis (4.3 Scheme 7). This would 
generate a range of alternative compounds which may have biological activity 
as analgesics. 
The lipase screen using the chirazyme® screening kit gave an interesting 
result in that lipase L-5 showed strong selectivity for the (S)-aminoalcohol 
(S)-89. This was opposite to all the other lipases screened and disaccords with 
Kaslauskas' empirical rules. As our objective was to improve the optical 
selectivity of the resolution, no further work was carried out using this lipase. 
Experimental 
5.0 Experimental 
5.0.1 General Experimental 
I  and 13C nmr were recorded on Perkin Elmer R34 220, Bruker AC 250, 
Bruker 300 or Bruker 400 instruments. Chemical shifts OH, 6c) are reported in 
ppm and coupling constants (J) are in Hertz (Hz). Chemical shifts were 
referenced to residual undeuteriated solvent present in the deuteriated 
sample, i.e. CHC13 in CDC13 for all but those recorded on the continuous wave 
Perkin Elmer R34 220. Chemical shifts for those recorded on the Perkin Elmer 
R34 220 were referenced to tetramethylsilane as internal standard. 
Fast atom bombardment (FAB) mass spectrometry was performed on a Kratos 
MS50TC spectrometer. 
Infra-red spectra were recorded on a Bruker Vector 22 FT-IR 
spectrophotometer with a golden gate ATR. The frequencies (v) were 
measured in wavenumbers (cm -1 ). Liquid samples were measured as thin 
films and solid samples were crushed in the diamond tipped probe and 
measured directly. 
Melting points were measured on a Reichert-Jung micro hot stage apparatus, 
and are quoted in °C and are uncorrected. 
Chiral HPLC analysis was carried out using Gilson hardware. A chiral-AGP 
column was used as the stationary phase for the methadone analyses, eluting 
with 0.01M sodium phosphate buffer pH 6.5: acetonitrile (840:160) with a flow 
rate of 0.9 ml mm- 1 . For the bufuralol analyses, a chiral Phenomenex 3022 
column was used eluting with hexane: 1,2-dichloroethane: ethanol (88:10:2) 
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with 5%  trifluoroacetic acid with a flow rate of 1.0 ml/min. Retention times 
(R) are quoted in minutes. 
Optical rotations were measured on an Optical Activity polAAr 2001 
polarimeter having a readability of ± 0.001° (sodium 589 nm detection). 
Sample concentration was measured in g/lOOml and [aID are quoted in 10-1 
deg cm 2  g 1 . 
Thin layer chromatography (tic) was carried out on aluminium plates coated 
with silica gel 60 F254, with detection by UV (254 nm) fluorescence, 
ammonium molybdate or potassium permanganate dips. Chromatography 
was carried out using silica gel 60 (Merck 7729). 
All reagents were used as supplied by commercial sources unless stated. 
Novozyme ® 435 was received as a gift from Novo-Nordisk and the 
Chirazyme ® Lipase and Esterase Screening Kit was received as a gift from 
Boehringer Mannheim. Dry solvents were used when necessary and were 
obtained from commercial sources. 
5.1 Bufuralol 
5.1.1 The route to 2-chloro-1-(7-ethylbenzofuran-2-yl)-1-hydroxyethane 80 
5.1.1.1 Preparation of 1-Allyloxy-2-ethylbenzene 74 62 
Experinwn tal 
Potassium carbonate (425g. 3.07mol) was added to a stirred solution of 
2-ethyiphenol (250g. 2.05mol) in dimethylformamide (900m1) at 0°C. Allyl 
bromide (212.5m1, 2.46mo1) and tetrabutylammonium bromide (10mg) were 
added and the mixture allowed to warm to room temperature and stirred for 
16 hours. Tlc (EtOAc:hexane, 1:4) showed complete reaction so the mixture 
was poured into water (3L) and extracted with ethyl acetate (3 x 1L). The 
combined extracts were washed with water (1L) and brine (1L) and dried over 
magnesium sulphate. Filtration and removal of the solvent under reduced 
pressure afforded the title compound 74 as an orange oil (331.6g, 99.8%). 
Rf (EtOAc:hexane, 1:4) 0.63 
vniax (neat)/cm 1 2965, 2930, 2872 (CH), 1237 (C-O) 
3H (CDC13; 250 MHz) 7.20 (2 H, m, CHar), 6.90 (2 H, m, CHar), 6.12 (1 H, m, 
CH2CH=CHAHB), 5.49 (1 H, dm, 117.3, CH2CH=CthHB), 5.32 (1 H, dm, J 
10.6, CH2CH=CHAHB), 4.60(2 H, dm, J4.9, CthCH=CHAHB),  2.73(2 H, q,J 
7.5, CH3CH2), 1.27(2 H, t, 17.5, CthCH2) 
6c (CDC13; 63 MHz) 156.3 (ipso-Ar, CO), 132.9 (ipso-Ar), 133.7 (CH2çH=CH2), 
129.0, 126.7, 120.6, 116.7 (CH ar), 111.4 (CHH=CH2), 68.6 (CH2CH=CH2), 23.4 
(H2CH3), 14.2 (CH2Cth) 
m/z (FAB) 91 (100%) 57 (18.3, OCH2CHCH2) 
5.1.1.2 Preparation of 2-Allyl-6-ethylphenol 7562 
A solution of 1-allyloxy-2-ethylbenzene 74 (331g, 2.04mol) was stirred at 
reflux in dimethylaniline (500ml) for 17 hours. Tlc (EtOAc:hexane, 1:4) 
M. 
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showed complete reaction so the solution was poured into concentrated 
hydrochloric acid (600m1) and ice (600m1) and this was shaken for 5 mins 
before ether (1L) was added. The layers were separated and the aqueous was 
extracted with more ether (2 x 1L) and the combined organics were washed 
with water (1L) and brine (1L) and dried (magnesium sulphate). The solvent 
was removed at reduced pressure to leave 75 as an orange/red oil (313.5g. 
94.7%). 
Rf (EtOAc:hexaine, 1:4) 0.50 
3H (CDC13; 250 MHz) 7.09 (1 H, dd, J7.4, 1.4, CH,), 7.01 (1 H, dd, J7.4, 1.6, 
Car), 6.88 (1 H, LI 7.4, Car), 6.03 (1 H, m, CH2CH=CH2), 5.25 (2 H, m, 
CH2CH=CH2), 5.06 (1 H, s, OH), 3.46 (2 H, d, 16.3, CthCH=CH2),  2.67 (2 H, q, 
J7.5, CH3CH2), 1.27 (2 H, t, J7.5, CthCH2). 
[lit. 63 5H (CDC13; 100MHz) 6.86 (1H, t, p-H), 4.94 (1H, d, OH), 5.0 (2H, m, 
CH2CHrCth), 5.2-5.8 (1H, m, CH2CH=CH2), 3.45 (2H, d, 16, CH2CH=CH2).] 
The NMR spectrum showed approximately 20% of the pam-product 
6H (CDC13; 250 MHz) 6.73 (1 H, d, J8.1, Cthr)  4.69 (1 H, s, Off 3.34 (2 H, d, J 
6.7, CJI2CH=CH2) 
5.1.1.3 Preparation of 3-Ethyl-2-hydroxy-5-methylstyrene 76 
Bis-(benzonitrile)-palladium (II) chloride (lg, cat.) was added to a solution of 
2-allyl-6-ethylphenol 75 (163g, lmol) in toluene (600ml) and the reaction 
mixture was stirred at reflux for 1 hour and then allowed to cool to room 
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temperature overnight. The toluene was removed at reduced pressure and the 
residue filtered through a plug of silica washing with diethyl ether (lOOmi). 
The ether was removed on the rotary evaporator and the styrene purified by 
distillation at reduced pressure (100-120°C @ 15 mm Hg). 3-Ethyl-2-hydroxy-
13-methyistyrene 76 was obtained as a pale yellow oil (142g, 87%). The 250 
MHz NMR spectrum showed this to be a mixture of the cis and trans products 
in a ratio of 1:2 respectively. 
trans-isomer:- 
Rf (EtOAc:hexane, 1:4) 0.48 
6H (CDC13; 250 MHz) 7.16 (1 H, dd, 1 7.5, 1.5, Car),  7.05 (1 H, d, J7.5, Car), 
6.87 (1 H, t, J 7.5,  Car), 6.60 (1 H, dd, 115.8, 1.5, ArCI-T=CHCH3), 6.20 (1 H, 
dq, 115.8, 6.6, ArCH=CHCH3), 5.08 (1 H, s, OH), 2.67 (2 H, q, J7.5, CH3Cth), 
1.95 (3 H, dd, 16.6, 17, ArCH=CHCth), 1.27 (2 H, t, J7.5, CthCH2). 
cis-isomer:- 
8H (CDC13; 250 MHz) 7.11 (1 H, d, J7.2, Car),  6.98 (1 H, dd, 1 7 .5, 1.8,  Car), 
6.88 (1 H, t, 17.4, CU,,), 6.43 (1 H, dd, 111.2, 1.4, ArCH=CHCH3), 6.07(1 H, 
dq, J11.2, 6.9, ArCH=CHCH3), 5.11 (1 H, s, OH), 2.66 (2 H, q, 1 7 .5 , CH3CU2), 
1.75 (3 H, dd, 16.9, 1.7, ArCH=CHCth), 1.27(2 H, t, 1 7.s, CthCH2). 
5.1.1.4 Ruthenium (III) chloride catalysed oxidative cleavage of styrene 76 
To a 5L flange flask fitted with a mechanical stirrer was added styrene 76 
(65g, 0.38mo1), sodium periodate (347g, 1.62mo1), carbon tetrachloride (1.5L), 
acetonitrile (1L), and water (1.5L). The resulting 2-phase mixture was stirred 
Me 
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and cooled to -4°C (ice/methanol bath) and anhydrous ruthenium (III) 
chloride (2g, cat.) was added in one portion. The temperature rose to 9°C over 
5 minutes and then after removal of the cooling bath to 27°C over a further 15 
minutes. The now darkened mixture was allowed to stir for 1.5 h to complete 
reaction. The solid was filtered off and the liquors extracted with ether (3 x 
1L). The combined extracts were washed with water (1L), brine (1L), and 
dried (sodium sulphate). Evaporation to dryness afforded crude 
benzaldehyde 77 as a dark oil. This was chromatographed on silica eluting 
with 0-3% ethyl acetate in hexane. Product containing fractions were pooled 
and evaporated to leave 3-ethyl-2-hydroxybenzaldehyde 77 as a yellow oil 
(14.2g, 25%). 
8H (CDC13; 220 MHz) 9.95 (1 H, s, UC=O), 7.45 (1 H, d, J 8, Cij,,), 7.00 (2 H, m, 
Car), 2.70 (2 H, q,J 7.5, CH3CH2), 1.25 (2 H, t, 1 7 .5, CthCH2). 
5.1.1.5 Osmium (VIII) oxide catalysed oxidative cleavage of styrene 76 
The styrene 76 (49g, 0.302mo1) was stirred in dioxane (200ml) at room 
temperature and a solution of osmium tetroxide ca. 0.8% (SOml) was added. 
Sodium periodate (132g, 0.617mo1) was added in portions over 30 minutes. 
The mixture was stirred at ambient temperature for 70 h and then diluted 
with water (2L) and extracted with ethyl acetate (2 x 1.5L). The combined 
organics were washed with brine (2L) and dried (magnesium sulphate). 
Evaporation afforded a dark oil which was purified by chromatography on 
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silica eluting with 0-3% ethyl acetate in hexane. 3-Ethyl-2-
hydroxybenzaldehyde 77 was obtained as a yellow oil (24.8g, 54.7%). 
8H (CDC13; 220 MHz) 9.98 (1 H, s, UC=O), 7.41 (1 H, d, J8, Cfl1),  6.95 (2 H, m, 
CH,), 2.65 (2 H, q,J 7.5, CH3CJJ2),  1.25 (2 H, t, J7.5, CthCH2). 
5.1.1.6 Preparation of 7-ethlbenzofuran-2-ylmethylketone 78 64 
To a stirred solution of the 3-ethyl-2-hydroxybenzaldehyde 77 (1g. 6.6mmol) 
and chioroacetone (0.92g, 10.0mmol) in ethanol (lOmi) was added potassium 
carbonate (1.84g, 13.3mmol) in portions over 30 minutes. The mixture was 
stirred at room temperature for 17 h. Water (lOOml) was added and the 
mixture extracted with dichloromethane (3 x lOOml). The combined extracts 
were washed with 2M sodium hydroxide solution (2 x lOOml), water (lOOml), 
brine (lOOml), and dried (magnesium sulphate). The solvent was removed 
under reduced pressure to leave an orange oil which was chromatographed 
on silica eluting with 0-3% ethyl acetate in hexane. Fractions containing 
product were pooled and evaporated to dryness to leave a pale oil which 
crystallised on standing (520mg, 41.9%). 
Rf (EtOAc:hexane, 1:4) 0.39 
Mp 56-58°C []it. 64  54.5°C 65 58-60°C] 
Vnax (neat)/cm 1 1678 (C=O) [lit. 65 V max  1682 cm 1 ] 
SI 
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8H (CDCI3; 250 MHz) 7.56 (1 H, dd, 17.5,1.5, CE8 ), 7.53 (1 H, s, Gifuran),  7.31 (2 
H, m, Cthr), 3.01 (2 H, q,  J7.5, CthCH3),  2.64 (3 H, s, CthCO),  1.39 (3 H, t, J 
7.5, CHCH3 
1 H NMR comparable to literature. 65 
5c (CDC1 3 ; 63 MHz) 188.2 (C=O), 154.4, 152.4 (C-8, C-2), 129.0, 126.7, 127.2, 
124.1, 120.6 (CH ar) 113.3 (C-3), 26.5 (EH3CO), 22.7 (CH2CH304.0 (CHCH3) 
m/z (FAB) 189 (100%, MH), 109 (28.8), 91 (99.1), 57 (24.7) 
5.1.1.7 Attempted preparation of 7-ethlbenzofuran-2-ylch1oromethy1ketone 
79 directly from 3-ethyl-2-hydroxybenzaldehyde 77 
The above procedure was followed but dichioroacetone was used instead of 
chioroacetone in an attempt to give the chioro ketone 79 directly. 
Unfortunately only baseline material was observed on tic. The same reaction 
was tried using DBU as the base but again no product was observed by tic. 
This route was abandoned. 
5.1.1.8 Preparation of 7-ethylbenzofuran-2-ylchloromethylketone 79 
Methylketone 78 (2g, 10.6mmol) was dissolved in dichloromethane (40m1) 
and stirred under an argon atmosphere at 0°C. Trimethylsilyltriflate (2m1, 
llmmol) was added followed by triethylamine (1.54m1, llmmol). The 
mixture was stirred for 1.5 h. N-chlorosuccinimide (1.42g. 10.6mmol) was 
added and the mixture allowed to warm to room temperature over 1 h. The 
reaction mixture was diluted with ethyl acetate (90m1) and washed with 10% 
aqueous sodium thiosulphate (3 x SOml), 10% aqueous sodium hydrogen 
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carbonate (3 x 50m1), brine (50m1), and dried (magnesium sulphate). The 
solvent was evaporated off under reduced pressure to leave a pale yellow oil 
which crystallised from ethanol to afford 79 as white crystals in two crops 
(512mg, 22.8%). 
Rf (EtOAc:hexane, 1:4) 0.43 
6f4 (CDC13 ; 220 MHz) 7.70 (1 H, s, CHfurai ), 7.60 (1 H, d, 17.6, Car), 7.35 (2 H, 
m, Cfj3,  4.75(2 H, s, C1CH2CO), 3.00(2 H, q, J7.5, CthCH3),  1.38(3 H, t, 1 
7.5, CHC 
1 H NMR comparable to literature. 65 
5.1.1.9 Reaction of 7-ethylbenzofuran-2-ylmethylketone 78 with sulphuryl 
chloride 65 
To a stirred solution of the methylketone 78 (2g, 10.6mmol) in chloroform 
(30ml) was added sulphuryl chloride (1.2m1, 14.8mmol). The resulting 
solution was heated to reflux and a small amount of 2M hydrochloric acid (4 
drops) was added. Heating at reflux was continued for a further 3 h and the 
solution was allowed to cool to room temperature overnight. Water (lOOmi) 
was added and the mixture extracted with dichloromethane (2 x lOOml). The 
combined organics were washed with brine (lOOml), dried (magnesium 
sulphate), and evaporated to dryness. The residue crystallised from ethanol to 
give a mixture of 7-ethylbenzofuran-2-yl chioromethyl ketone 79, k (220MHZ 
CDC13) 7.2-7.7 (4 H, m, Car),  4.73 (2 H, s, C1CU2CO),  3.0 (2 H, q, J 7.5 
CH2CH3), 1.36 (3 H, t, 1 7.5, CH2CH3) and 7-ethylbenzofuran-2-yl 
dichloromethyl ketone, 5H  (220MHz; CDC13) 7.89 (1 H, s, CUftiraji), 7.27.7 (3 H, 




5.1.1.10 Preparation of 2-chloro-1-(7-ethylbenzofuran-2-yl)-1-hdroxethane 
Cl
01  
Sodium borohydride (85mg, 2.3mmol) was added to a stirred solution of the 
chioroketone 79 (510mg, 2.3mmol) in ethanol (15m1) at 10°C (cold water bath). 
The reaction was complete after lh. The ethanol was evaporated at reduced 
pressure and the residue partitioned between water (SOml) and ethyl acetate 
(50m1). The aqueous was separated and extracted with more ethyl acetate (2 x 
50m1). The combined organics were washed with brine (50m1), dried 
(magnesium sulphate), and evaporated to dryness to leave 80 as a yellow oil 
(512mg, 99.5%). 
Rf (EtOAc:hexane, 1:4) 0.30 
oH (CDC13; 250 MHz) 7.42 (1 H, dd, J7.6,1.5, Cjj), 7.15 (2 H, m, CH,), 6.78 (1 
H, s, Cauran),  5.12 (1 H, m, CH(OH)), 3.96 (2 H, m, C1CH2CH(OH)), 2.95 (2 H, 
q, J7.5, CthCH3), 2.70 (1 H, brs, OH),  1.36 (3 H, t, 1 7 . 5 , CH2CU3). 
'H NMR comparable with literature. 65 
5.1.2 Lipase catalysed resolutions using trifluoroethyl octanoate 
5.1.2.1 Preparation of trifluoroethyl octanoate ester 
0 	CF3 
To a solution of 2,2,2-trifluoroethanol (20g, 0.2mol) and DMAP (20mg, cat.) in 
dichloromethane (200m1) under argon was added pyridine (24m1, 0.3mol) and 
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octanoyl chloride (32.5g, 0.2mol) dropwise. Once the addition was complete 
the reaction was allowed to stir at room temperature for 1 h and then diluted 
with dichloromethane (200ml). The organic solution was washed with 0.1M 
hydrochloric acid (2 x 200m1), saturated sodium hydrogen carbonate solution 
(200m1), brine (lOOml), and dried (magnesium sulphate). Evaporation to 
dryness followed by distillation at reduced pressure afforded the title 
compound as a clear oil (35.2g, 77.9%). 
3H (CDC1 3; 220 MHz) 4.40 (2 H, m, OCH2CF3), 2.35 (2 H, t, J 7.5, CH2Cfl2CO), 
1.60 (2 H, m, CH2CH2CO), 1.25 (8 H, br s, methylene Hs), 0.80 (3 H, br t, 
CthCH2). 
5.1.2.2 Preparation of racemic 2-chloro-1-(7-ethylbenzofuran-2-yl)-1-ethyl 
octanoate 81 
0 	bCOC7 H 15 
Pyridine (lml) and octanoyl chloride (90mg, 0.55mmol) were added to a 
solution of the chloroalcohol 80 (90mg, 0.4mmol) in dichloromethane (lOml) 
containing DMAP (2mg, cat.) under argon at room temperature. The reaction 
mixture was stirred for lh and tic (ethyl acetate:hexane, 1:4) showed complete 
conversion. The reaction mixture was diluted with dichloromethane (30m1) 
and washed with 0.1M hydrochloric acid (2 x SOml), saturated sodium 
hydrogen carbonate (SOml), and brine (50ml). After drying over magnesium 
sulphate the solvent was removed at reduced pressure to leave the title 
compound 81 (55mg, 40%). 
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R (EtOAc:hexane, 1:4) 0.55 
3H (CDC13; 300 MHz) 7.44 (1 H, dd, 1 7 s, 1.5,  C1j3,  7.20 (2 H, m, CH.,), 6.82 (1 
H, s, CHfurail ), 6.23 (1 H, t, 16.5, CH(OOct)) 4.04 (2 H, d, 16.5, 
C1CH2CH(OOct)), 2.96 (2 H, q, 1 7 . 5, ArCH2CH3), 2.44 (2 H, dt, 16.0, 15, 
CH2CH2C=O), 1.70 (2 H, m, CthCH2CO), 1.35 (3 H, t, J7.5, ArCH2Cth), 1.30 
(8 H, m, methylene Hs), 0.90 (3 H, br t, CthCH2CH2). 
5.1.2.3 Lipase catalysed esterification of the racemic chioroalcohol 80 
The resolution was carried out using four lipases from Amano. These were 
lipase AP, lipase AY, lipase M, and lipase PS. The following procedure is 
representative. The chioroalcohol 80 (90mg, 0.4mmol) and trifluoroethyl 
octanoate ester (230mg, lmmol) were dissolved in benzene-hexane (1:9 v/v, 
lOmi). The lipase (300mg) was added and the mixture shaken at 45°C for 70 h. 
The progress of these reactions was monitored by tic using ethyl acetate-
hexane (1:4 v/v). The resolutions using lipase AP and lipase M showed only 
trace amount of ester and this was not isolated. Lipase AY showed 
approximately 20% conversion by tic and lipase PS showed less than 10% 
conversion to the ester. The lipase from these reactions was removed by 
filtration and the octanoate ester and remaining alcohol were separated by 
chromatography on silica gel with ethyl acetate-hexane (3-5% v/v). Table 3 
shows the amounts isolated for each lipase and the optical purity of the 
octanoate ester as determined by shift reagent NMR spectroscopy using a 
chiral europium reagent - Eu(hfc)3. 
The Rf value and the 'H NMR spectrum at 300MHz for the octanoate esters 
obtained from these resolutions were identical to that of the racemic octanoate 




Lipase Amt of Ester 81 Amt of Alcohol 80 1  cc of Ester 81 
Lipase AY 26mg, 19% 60mg, 67% 
Lipase PS 2mg, 1% 82mg, 91% >99% 
5.1.3 Lipase catalysed resolutions using vinyl acetate as the acyl donor and 
subsequent conversion to bufuralol 
5.1.3.1 Lipase AY catalysed acetylatiori of the chioroalcohol 80 with vinyl 
acetate 
H 3 
The chloroalcohol 80 (90mg, 0.401mmol) was dissolved in vinyl acetate (5m1). 
Lipase AY (500mg) was added and the mixture gently stirred at room 
temperature for 48h. After this time tic (ethyl acetate:hexane, 1:4) showed 
approximately 50% conversion. The lipase was removed by filtration through 
celite and the residue was washed with ethyl acetate. The solution was 
evaporated to dryness at reduced pressure and the resolution products were 
separated by chromatography on silica gel eluting with ethyl acetate-hexane 
(3-5% v/v). The first compound to be eluted was the (5)-acetate (S)-82 and 
after removal of the solvent it was obtained as a clear oil (25mg, 18%). 
R (EtOAc:hexane, 1:4) 0.50 
5H (CDC13; 250 MHz) 7.42 (1 H, dd, J7.4, 1.8, Car), 7.18 (2 H, m, Car), 6.81 (1 
H, s, Cll furan), 6.20 (1 H, t, 16.4, CH(OAc)) 4.01 (2 H, d, J 6.4, C1CthCH(OAc)), 




Further elution afforded the more polar (R)-alcohol (R)-80 after evaporation as 
a clear oil (27mg, 27%). 
Rf (EtOAc:hexane, 1:4) 0.30 
oH (CDC13 ; 250 MHz) 7.42 (1 H, dd, 17.6,1.5, CH,), 7.15 (2 H, m, CH,), 6.78 (1 
H, s, CUfurai1),  5.12 (1 H, m, CH(OH)), 3.96 (2 H, s, C1Cfl2CH(OH)),  2.95 (2 H, 
q, J 7.5,  CthCH3),  2.70 (1 H, brs, OH), 1.36 (3 H, t, J7.5, CH2Cth). 
Optical purity was not measured at this stage and the assignment of absolute 
configuration was done by chiral HPLC analysis of the bufuralol produced 
from these compounds. 
5.1.3.2 Lipase AY catalysed hydrolysis of (S'-2-chloro-1-(7-ethylbenzofuran-2-
yl)-1-ethyl acetate (S)-82 
CI 
The (S)-acetate (S)-82 (25mg, 0.094mmol) from the previous experiment 
(5.1.3.1) was dissolved in acetone (lml) and 0.1M potassium phosphate buffer 
solution at pH 7.0 (5m1) was added. The mixture was stirred at room 
temperature and lipase AY (100mg) was added in one portion. The course of 
the reaction was monitored by tic (ethyl acetate:hexane, 1:4) and the pH was 
checked periodically and maintained at pH 7 by the addition of small portions 
of 0.01M sodium hydroxide solution. After approximately 48h the reaction 
appeared to have reached 60% hydrolysis so diethyl ether (40ml) was added 
and the phases were allowed to separate. The aqueous layer was extracted 
with diethyl ether (3 x 40m1) and the combined extracts were washed with 
brine (30ml) and dried (magnesium sulphate). The solvent was removed 
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under reduced pressure and the residue chromatographed over silica gel 
elating with ethyl acetate-hexane (3-5% v/v). The (5)-alcohol (S)-80 was 
obtained as a colourless gum (13mg, 62%) 
Rf (EtOAc:hexane, 1:4) 0.30 
3H (CDC1 3; 250 MHz) 7.42 (1 H, dd, 17.6,1.5, CH,), 7.15 (2 H, m, CHar), 6.78 (1 
H, s, CHfuraij, 5.12 (1 H, m, CH(OH)), 3.96 (2 H, s, C1CH2CH(OH)), 2.95 (2 H, 
q, 1 7.5,  CthCH3), 2.70 (1 H, brs, OH), 1.36 (3 H, t, 17.5, CH2CH3). 
The unhydrolysed (5)-acetate (S)-82 was recovered and this was also isolated 
as a gum (10mg, 40%). 
Rf (EtOAc:hexane, 1:4) 0.50 
3H (CDC1 3; 250 MHz) 7.42 (1 H, dd, 1 7 .4, 1.8, CHar), 7.18 (2 H, m, Car),  6.81 (1 
H, s, Chiuran), 6.20 (1 H, t, 16.4, CH(OAc)) 4.01 (2 H, d, 16.4, ClCCH(OAc)), 
2.95 (2 H, q, J 7.5,  CthCH3), 2.20 (3 H, s, Cjj3C=O), 1.35 (3 H, t, J7.6, 
CH2CH3). 
5.1.3.3 Preparation of (R)-(+'-Bufuralol (R')-60 from the (S'-alcohol (S')-80 
isolated from the Lipase AY resolution 37 
NHBu t 
Potassium carbonate (12mg, 0.087mmol), potassium iodide (5mg, 0.030mmol), 
and tert-butylamine (150j.tl, 1.45mmol) were added to a solution of the (5)-
alcohol (5)-80 (13mg, 0.058mmol) in dimethylformamide (2m1) and the 
reaction mixture was heated at reflux for 7h. Tlc (methanol:dichloromethane, 
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1:9) showed no remaining starting material so the reaction mixture was 
evaporated to dryness tinder reduced pressure (high vacuum). The residue 
was dissolved in ethyl acetate (20ml) and washed with water (2 x 30m1). The 
product was extracted with 5% citric acid (2 x lOml) and the acid extracts 
were backwashed with ethyl acetate (lOmi). The acid layer was then 
neutralised by the slow addition of 2M sodium hydroxide solution. The 
product was extracted with dichloromethane (3 x 20m1) and after drying over 
magnesium sulphate the solvent was removed at reduced pressure to afford 
(R)-(+).-Bufuralol (R)-60 (7mg, 47%) as a yellow oil. ee = 50%. 
Rf (MeOH:CH202, 1:9) 0.41 
["ID +14° (c 0.25, EtOH) 
6H (CDC13; 250MHz) 7.37 (1 H, dd, 11.5, 7.4, Car),  7.14 (2 H, m, CjjJ, 6.63 (1 
H, s, CHfUr j, 4.13 (1 H, dd, 19.0,  4.9,  CHx(OH)CHAHB), 3.74 (1 H, dd, 110.6, 
4.9, CHx(OH)CHAHB), 3.60 (1 H, dd, J 10.6, 9.0, CHX(OH)CHAUB), 2.95 (2 H, 
q, J 7.6, CjjCH3), 2.83 (2 H, br s, NH and OH), 1.37 (3 H, t, J 7.6, CH2Cth), 
1.16 (9 H, s, tBu) 




The chloroalcohol 80 (90mg, 0.401mmol) was dissolved in vinyl acetate (Sml). 
Lipase PS (500mg) was added and the mixture gently stirred at room 
temperature for 48h. After this time tic (ethyl acetate:hexane, 1:4) showed 
approximately 50% conversion. The lipase was removed by filtration through 
[till 
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celite and the residue was washed with ethyl acetate. The solution was 
evaporated to dryness at reduced pressure and the resolution products were 
separated by chromatography on silica gel eluting with ethyl acetate-hexane 
(35% v/v). The first compound to be eluted was the (5)-acetate (S)-82 and 
after removal of the solvent it was obtained as a clear oil (45mg, 44%). Further 
elution afforded the more polar (R)-alcohol (R)-80 after evaporation as a clear 
oil (35mg, 39%). Optical purity was not measured at this stage and the 
assignment of absolute configuration was done by chiral HPLC analysis of the 
bufuralol produced from these compounds. 
5.1.3.5 Lipase PS catalysed hydrolysis of (S'-2-chloro-1-(-ethylbenzofuran-2-
yl)-1-ethyl acetate (S)-82 
CI 
The (5)-acetate (S)-82 (45mg, 0.169mmol) from the previous experiment was 
dissolved in acetone (lml) and 0.1M potassium phosphate buffer solution at 
pH 7.0 (5m1) was added. The mixture was stirred at room temperature and 
lipase PS (lOOmg) was added in one portion. The course of the reaction was 
monitored by tic (ethyl acetate:hexane, 1:4) and the pH was checked 
periodically and maintained at pH 7 by the addition of small portions of 
0.01M sodium hydroxide solution. After approximately 48h the reaction 
appeared to have reached 50% hydrolysis so diethyl ether (40m1) was added 
and the phases were allowed to separate. The aqueous layer was extracted 
with diethyl ether (3 x 40m1) and the combined extracts were washed with 
brine (30m1) and dried (magnesium sulphate). The solvent was removed 
under reduced pressure and the residue chromatographed on silica gel 
[31 
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eluting with ethyl acetate-hexane (3-5% v/v). The (5)-alcohol (S)-80 was 
obtained as a colourless gum (20mg, 53%). The unhydrolysed (5)-acetate 
(S)-82 was recovered and this was also isolated as a gum (20mg, 44%). 
5.1.3.6 Preparation of (R)-(+)-Bufuralol 0-60 from the (s-alcohol (S')-80 
isolated from the Lipase PS resolution 3 
NHBu t 
Potassium carbonate (18mg, 0.134mmol), potassium iodide (7mg, 0.045mmol), 
and tert-butylamine (230 p1, 2.23mmol) were added to a solution of the (5)-
alcohol (5)-80 (20mg, 0.089mmol) in dimethylformamide (2m1) and the 
reaction mixture was heated at reflux for 7h. Tlc (methanol:dichloromethane, 
1:9) showed no remaining starting material so the reaction mixture was 
evaporated to dryness under reduced pressure (high vacuum). The residue 
was dissolved in ethyl acetate (20m1) and washed with water (2 x 30m1). The 
product was extracted with 5% citric acid (2 x lOml) and the acid extracts 
were backwashed with ethyl acetate (lOml). The acid layer was then 
neutralised by the slow addition of 2M sodium hydroxide solution. The 
product was extracted with dichloromethane (3 x 20m1) and after drying over 
magnesium sulphate the solvent was removed at reduced pressure to afford 
(R)-(+)-Bufuralol (R)-60 (13mg, 56%) as a yellow oil. ee = 90%. 
Rf (MeOH:CH2 C12 , 1:9) 0.41 
[aID +23 0 (c 0.25, EtOH) 
6H (CDCI3 ; 250MHz) 7.37 (1 H, dd, J 1.5, 7.4, CHar), 7.14 (2 H, m, Cth),  6.63 (1 
H, s, CHiurai.), 4.13 (1 H, dd, 19.0, 4.9, CHx(OH)CHAHB),  3.74 (1 H, dd, 1 10.6, 
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4.9, CHX(OH)CHAHB),  3.60 (1 H, dd, J 10.6, 9.0, CHX(OH)CHAHB), 2.95 (2 H, 
q, 17.6, CthCH3),  2.83 (2 H, br s, NH and OH), 1.37 (3 H, t, J7.6, CH2CH3), 
1.16 (9 H, s, tBu) 
5c (CDC13; 63MHz) 157.5, 153.0, 128.0, 127.6, 123.3, 123.0, 118.4, 103.5, 64.4, 
52.8, 52.2, 29.6, 23.0, 14.1 
5.2 Methadone 
5.2.1 Resolutions with vinyl acetate 
5.2.1.1 Resolution of 1-dimethylamino-2-12ropanol 89 
Me2N'( 	 Me2N"( + Me 2N'' 
OH 	 OCOCH 3 	OH 
Racemic 1-dimethylamino-2-propanol 89 (2g, 19.4mmol) was stirred with 
vinyl acetate (lOmI) at ambient temperature and Lipase PS (500mg) was 
added. The reaction mixture was stirred slowly for 42h and after this time tic 
(10% methanol! dichioromethane - visualise KMn04 solution) indicated that 
the reaction had gone to approximately 50% conversion. The enzyme was 
removed by filtration and the filter bed was washed with ethyl acetate (2 x 
20m1). The solution was evaporated to leave a yellow oil which was 
chromatographed on silica (SOg) elating with 0-10 % methanol in 
dichloromethane to afford (-)-1-dimethylamino-2-propyl acetate 91 (1.7g. 
60%) as a clear oil. 
J-I (CDC13; 400 MHz) 5.03 (1 H, sextet, J7, CH3CH(OCOCH3 )), 2.50 (1H, dd, J 
10, 7, N-CHAHBCH(OCOCHI)), 2.23 (6 H, s, N(Cj±)2), 2.22 (1H, dd, J 10, 7, 
N-CHAH13CH(OCOCH3)), 2.02 (3H, s, CH3CO), 1.21 (3 H, d, J7, 
CthCH(OCOCH3)) 
ee = 46%. The ee of the product was determined by shift reagent NMR using 




The remaining alcohol could not be isolated from the column despite eluting 
with 50% methanol in dichloromethane. 
5.2.1.2 Resolution of 1-dimethylamino-2-12ropanol 89 
Racemic 1-dimethylamino-2-propanol 89 (ig, 9.7mmol) was stirred with vinyl 
acetate (3ml) at ambient temperature and Lipase PS (250mg) was added. The 
reaction mixture was stirred slowly for 16h and after this time tic (10% 
methanol! dichloromethane - visualise KMn0 4 solution) indicated that the 
reaction had gone to approximately 30% conversion. The enzyme was 
removed by filtration and the filter bed was washed with ethyl acetate (2 x 
20m1). The solution was evaporated to leave a yellow oil which was 
chromatographed on silica (30g) eluting with 0-10 % methanol in 
dichloromethane to afford (-)-1-dimethylamino-2-propyl acetate 91 (471mg, 
33%) as a clear oil. 
8H (CDC13. 400 MHz) 5.03 (1 H, sextet, J7, CH3CH(OCOCH3 )), 2.50 (1 H, dd, J 
10, 7, N-CjjH5CH(QCOCH 3)), 2.23 (6 H, s, N(C)2), 2.22 (1 H, dd, 110, 7, 
NCHAilBCH(OCOCH3)), 2.02(3 H, s, CthCO),  1.21 (3H, d,J7, 
CthCH(OCOCH3)) 
ee =90%. The ee of the product was determined by shift reagent NMR using 
Eu(hfc)3. 
The remaining alcohol could not be isolated from the column despite eluting 
with 50% methanol in dichloromethane. 
UP 
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5.2.2 Resolution of 1-dimethylamino-2-propanol using vinyl propanoate 
and reaction of the resolution products to methadone 
5.2.2.1 (R)-(-')-1-dimethylamino-2-12ropyl propanoate (10-92 
Me2 N 
000CH 3 
Racemic 1-dimethylamino-2-propanol 89 (100g. 0.97mo1) was stirred with 
vinyl propanoate (106m1, 0.97mo1) at ambient temperature and Novozyme ® 
435 (6g) was added. The reaction mixture was stirred slowly for 70 hours and 
after this time tic (10% methanol/dichloromethane - visualise KMn04 
solution) indicated that the reaction had gone to 50% conversion. The enzyme 
was removed by filtration and the filter bed was washed with ethyl acetate (2 
x lOOml). The organic layer was then washed with water (4 x 400mi) and the 
combined washes were back extracted with ethyl acetate (400m1). The organic 
layer was then washed with brine (200m1) and dried (MgSO4). The ethyl 
acetate was removed in vacuo to leave 58.7g (0.37mo1, 35% - maximum yield 
50%) of (R)-(-)-1-dimethylamino-2-propyl propanoate (R)-92 as a yellow oil. 
Rf (Methanol:dichloromethane, 1:9) 0.38 
vnax (neat)/cm 1 2978, 2941, 2821, 2768 (CH), 1732 (C=O) 
3H (CDC13; 250 MHz) 5.05 (1 H, m, CH 3CH(OCOC2H5)), 2.51(1 H, dd, 112.9, 
7.4, N-CUAHBCH(OCOC2H5)), 2.30(3 H, m, N-CHAUBCH(OCOCthCH3)), 
2.25 (6 H, s, N(Cff3)2),  1.21 (3 H, d, 16.3, CthCH(OCOC2H5)), 1.11 (3 H, t, J 
7.5, OCOCH2Cth) 
& (CDC13; 63 MHz) 174.0 (C=O), 68.1 (CH-O), 64.0 (CH2-N), 45.8 ((çH3)2N), 
27.8 (COCH2CH3), 18.5 (CH3CH), 9.0 (COCH2CH3) 
The optical purity was not measured at this stage. 
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5.2.2.2 (Th-(-)-1-Dimethvlamino-2-12ro42anol (R)-89 
Me2N 
OH 
A solution of sodium methoxide was made by dropping small pieces of 
sodium metal (200 mg) into methanol (5 ml) under an atmosphere of argon. 
This was then added to a stirred solution of (-)-1-dimethylamino-2-propyl 
propanoate (57.7g, 0.36mo1) in methanol (200m1). The mixture was stirred 
overnight and checked for completion by tic (10% 
methanol/dichloromethane). The methanol was removed under reduced 
pressure to leave (R)-(-)-1-dimethylamino-2-propanol (R)-89 (32.8g, 88%) as a 
dark oil. 
Rf (Methanol:dichloromethane, 1:9) 0.18 
v rnax (neat)/cm' 3419 (OH) 2969, 2819, 2772 (CH) 
3H (CDC13; 250 MHz) 3.76 (1 H, m, CH3CH(OH)), 3.49 (1 H, brs, OH), 2.24 (6 
H, s, N(CH 3 )2), 2.15 (2 H, m, NCR 2) 1.10 (3 H, d, J6.1, CthCH(OH)) 
c (CDC13; 63 MHz) 67.0 (CH(OH)), 63.0 (CH2-N), 45.4 ((H3)2N), 20.0 
(CH3CH) 
5.2.2.3 (S)+)-1-Dimethylamino-2-chloropropane hydrochloride (S)-90 49,66 
Me2 HN 
Cl - 	ci 
A solution of thionyl chloride (37ml, 0.48mol) in chloroform (20m1) was added 
slowly, with stirring, to a cooled (ice/water) solution of (R)-(-)-1-
dimethylamino-2-propanol (R)-89 (31.8g, 0.32mo1) in chloroform (85 ml). 
When the addition was complete a precipitate formed. The mixture was 
allowed to warm to room temperature over 30 minutes and then heated to 
r;n 
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reflux for a further 30 minutes. The precipitate redissolved on heating but 
then the product crystallised out from the boiling solvent as it formed. More 
chloroform (20m1) was needed to maintain the stirring. The cooled mixture 
was diluted with ether and filtered. The crude product (45.2g,89%) was 
recrystallised from 2-propanol and decolourising charcoal was used. The 
product (33.1g, 65%) was obtained in 3 crops and the first crop (24.5g) was 
kept separate; [aID  +59.1 0  (c 2.075, H20). This material was recrystallised twice 
more to give lS.?g, 31% of (S)-(+)-1-dimethylamino-2-chloropropane 
hydrochloride (S)-90. 
Mp 192-193°C 
[cxJD+65.9 0 (c 2.01, H20) 
vm , x(solid)/cm 1 2962 (CH) 
3H (D20; 250 MHz)) 4.42 (1 H, sextet, J7.0, CH2CHC1CH3), 3.40 (2 H, d, 18.0, 
NCU2CHC1), 2.88 (6 H, d, J8.4, N(Cth)2), 1.49 (3 H, d, 16.5, CthCHC 1 ) 
& (DO; 63 MHz) 64.3 (CHC1), 52.0 (CH2N), 45.6 (CH3N), 41.8 (H3N), 22.3 
(cH3CH) 
jn/z (FAB) 124 (26.7%, MH, Cl), 122 (100, MH, Cl), 86 (8.5, MC1), 44 (11.0, 
N(CH3)2) 
5.2.2.4 (R')-(-)-2,2-Diphenyl-4-dimethylaminopentanenjtrile (R)-86 55 
CN 
Me2N Ph Ph 
A 50% w/v solution of sodium hydroxide in water (12.5m1, 0.32mo1) was 
added to a mechanically stirred suspension of diphenylacetonitrile (15.0g. 
0.08mol) and dibenzo-18-crown-6 (O.Sg, cat.) in dimethylsulphoxide (12.5ml). 
The colour rapidly deepened to an orange/brown. (S)-(+)-1-dimethylamino-2-
chioropropane hydrochloride (S)-90 (15g, 0.095mo1) was added in portions 
Sh 
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over 30 minutes, this caused the temperature to rise to 30°C. After the 
addition was complete the mixture was warmed to 45-50°C (water bath) and 
stirred for a further hour. The reaction mixture was then allowed to cool to 
room temperature and was poured into ice/water (250m1) and extracted with 
ethyl acetate (3 x 150m1). The combined extracts were dried (MgSO4), filtered, 
and concentrated to -lOOml. The product was extracted into IN HCl (iOOml + 
50ml) and this was back washed with ethyl acetate. The aqueous was basified 
with 2M sodium hydroxide and extracted into ethyl acetate (3 x lOOml). The 
extracts were washed with brine (ZOml), dried (MgSO4), and evaporated to 
yield a yellow oil. This was chilled and triturated with cold hexane (-SOml) to 
give a white solid which was collected by filtration and washed thoroughly 
with a further portion of cold hexane (lOOml). The solid was recrystallised 
from hexane to afford (R)-86 (7.0g. 32%). 
Rf (Methanoi:dichloromethane, 1:9) 0.45 
Mp 100-101 °C 
[aID -50.2 0 (c 0.71, EtOH) 
vmax(solid)/cm1 2972, 2938, 2819, 2774 (CH), 2229 (CN) 
6i- (CDC13 ; 250 MHz) 7.38 (10 H, m, CH,), 2.70 (1 H, dd, 113.6, 6.4, 
CHCHACHBCPh2), 2.54 (1 H, sextet, 16.3, CH3CHCHACHB), 2.25 (1 H, dd, J 
13.6, 6.0, CHCHACHBCPh2), 2.15 (6 H, s, N(C5)2),  0.92 (3 H, d, 16.5, CthCH) 
3c (CDC13; 63 MHz) 141.2, 140.6 (ipso-Ar), 128.7, 128.6, 127.8, 127.6, 127.3, 
127.1 (CH,,), 122.8 N), 55.4 (CH3CH), 49.6 (Ph2CN), 43.2 (N(CH3)2), 39.9 
(CH203.1 (CH3 CH) 
rn/z (FAB) 289 (4.9%, MH), 279 (100), 154 (23, Ph2), 137 (14), 72 (45, 
CH3CHN(CH 3 ) 2 ) 
1.-I.' 
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5.2.2.5 (R)- (-)-Methadone hydrochloride (R)-83 30 
Me2N Ph Ph 
All apparatus was dried and the reaction was carried out under an inert 
atmosphere of argon. A solution of (R)-(-)-2,2-diphenyl-4-
dimethylaminopentanenitrile (R)-86 (5.0g, 0.018mol) in toluene (15m1) was 
added to a stirred solution of 3M ethylmagnesium bromide in ether (10.7m1, 
0.03mol). The ether was removed under reduced pressure and the remaining 
solution heated at reflux (135-140°) for 3 hours. The solution went slightly 
cloudy but there was no significant precipitation. After cooling to room 
temperature 2N HC1 (30m1) was added with care and then stirring was 
continued at 135-140° for a further 30 minutes. The two phases were allowed 
to separate and cool to room temperature. After scratching the sides of the 
flask a solid started to crystallise from the aqueous phase. The flask was 
cooled to complete crystallisation and the white solid was collected by 
filtration. This solid was recrystallised from water to yield 2.7g (43%) of 
(R)-(-)-methadone hydrochloride (R)-83 (6-dimethylamino-4,4-diphenyl-3-
heptanone hydrochloride) 
R t 9.7 (99.8%) - Racemic - 10.0, 13.1 
Mp 242-244 1 , 
[aID -136 0 (c 2.04, EtOH) 
vijax (solid)/cm 1 2935 (CH), 2462, 1702 (C=O) 
6H (d6DMSQ; 250 MHz) 7.07-7.57 (10 H, m, CH,), 3.08 (1 H, brd, 114.0, 
CHCL-JACHBCPh2), 2.93 (1 H, m, CH3CHCHACHB), 2.67(6 H, brd, N(C1)2), 
2.40 (1 H, m, CHCHACHBCPh2), 2.20 (2 H, q, J7.3, CH3CH2CO), 0.73 (3 H, t, J 
7.2, CftCH2CO), 0.43 (3 H, d, 16.6, CthCH) 
Nfl' 
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S (d6DMSO; 63 MHz) 140.7, 140.3 (ipso-Ar), 129.4, 129.2, 129.0, 128.7, 127.8, 
127.0 (CHar), 64.8 (CHH), 59.1 (CPh2CO), 38.5, 38.3 (CHCH2CPh2 and 
N(H3)2), 32.6 (CH2CO), 14.9, 9.5 (CH3CH and CH3CH2) 
;n/z (FAB) 310(100%, MH), 265 (11, M-N(CH 3 )2), 154 (19, Ph2), 72 (15, 
CH3CHN(CH3)2) 
Chiral HPLC shows no evidence of (5)-isomer (S)-83 - cc >99% 
5.2.2.6 (S)-(+)-1-Dimethvlamino-2-12ropanol (5)-89 
Me2 N 
OH 
Racemic 1-dimethylamino-2-propanol 89 (bOg, 0.97mo1) was stirred with 
vinyl propionate (63.6m1, 0.58mol) at 40°C and Novozyme ® 435 (5g) was 
added. The reaction mixture was stirred slowly for 75 hours and after this 
time tic (10% methanol/dichioromethane - visualise KMn04 solution) 
indicated that the reaction had gone to at least 50% conversion. The enzyme 
was removed by filtration and the filtrate was distilled at reduced pressure. 
(S)-(+)-1-dimethylamino-2-propanol (S)-89 was obtained as a colourless oil 
(31.6g, 64%) bpt 35°C, 5mm Hg, 
[aID +23° (c 2.10, EtOH) [lit. 49  +24° (c 2.17, EtOH)] 
R (Methanol:dichloromethane, 1:9) 0.19 
vniax(neat)/cm 1 2978, 2941, 2821, 2768 (CH), 1732 (C=O) 
3H (CDC13; 250 MHz) 5.05 (1 H, m, CH3CH(OCOC2H5)), 2.51(1 H, dd, 112.9, 
7.4, N-CLIAHBCH(OCOC2H5)), 2.30(3 H, m, N -CHAHBCH(OCOCJ±CH3)), 




& (CDC13; 63 MHz) 174.0 (C=O), 68.1 (CH-0), 64.0 (çH2-N),  45.8 (LH3)2N), 
27.8 (COCH2CH3), 18.5 (cH3CH), 9.0 (COCH2CH3) 
5.2.2.7 (R'-(-)-1-Dimethylamino-2-chloropropane hydrochloride (R)-90 49,66 
Me2 HN 
CL 	Cl 
This was prepared following the same procedure as the (S)-isomer (5.2.2.3). 
30.6g of (S)-89 were used and 45.Og (96%) of crude product was isolated. This 
was recrystallised from 2-propanol as in the other series to give 30.9g (65%) of 
(R)-90. 
Mp 192-193°C [lit. 49  192-193°C] 
[aID -65.80 (c 2.0, H20) [lit. 49  -650 (c 2.01, H20)] 
vmax (solid)/cnv 1 2962 (CH) 
3H (D20; 250 MHz)) 4.42 (1 H, sextet, J7.0, CH2CHC1CH3), 3.40 (2 H, d, I 8.0, 
NCU2CHC1), 2.88 (6 H, d, J8.4, N(Cth)2), 1.49 (3 H, d, J6.5, CIISCHC1) 
c (D20 63 MHz) 64.3 (CHC1), 52.0 (CH2N), 45.6 (CH3N), 41.8 (H3N), 22.3 
(CH3CH) 
rn/z (FAB) 124 (26.7%, MH, Cl), 122 (100, MH, Cl), 86 (8.5, MCI), 44 (11.0, 
N(CH3)2) 
5.2.2.8 (S4+-2 ,2-Diphenvl-4-dimethylaminopentanenitrile (S-86 55 
Me2N Ph Ph 
This was prepared following the same procedure as the (R)-isomer (5.2.2-4). 55  
30g of (R)-90 were used and 14.65g (33%) of (S)-(+)-2,2-diphenyl-4-
dimethylaminopentanenitrile (S)-86 were obtained. 
91 
Experimental 
Mp 100-101°C [lit. 49,46 100-101°C] 
[aID +52.9° (c 0.66, EtOH) [lit. 4949°  (c 0.68, EtOH)] 
v 1 (solid)/cm 1 2972, 2938, 2819, 2774 (CH), 2229 (CN) 
5 fT (CDC13; 250 MHz) 7.38 (10 H, m, Cu), 2.70 (1 H, dd, 113.6, 6.4, 
CHCHACH13CPh2), 2.54 (1 H, sextet, J6.3, CH3CHCHACH13), 2.25 (1 H, dd, J 
13.6, 6.0, CHCHACHBCPh2), 2.15 (6 H, s, N(Cth)2), 0.92 (3 H, d, 16.5, CthCH) 
6c (CDC13 ; 63 MHz) 141.2, 140.6 (ipso-Ar), 128.7, 128.6, 127.8, 127.6, 127.3, 
127.1 (CHar), 122.8 N), 55.4 (CH3CH), 49.6 (CPh2CN), 43.2 (NLH3)2), 39.9 
(H2), 13.1 (H3CH) 
m/z (FAB) 289 (4.9%, MH), 279 (100), 154 (23, Ph2), 137 (14), 72 (45, 
CH3CHN(CH3) 2 ) 
5.2.2.9 (S)-(+)-Methadone hydrochloride (S')-83 30 
Me2N Ph Ph 
This was prepared following the same procedure as the (R)-isomer (5.2.2.5). 
log of (S)-86 were used and 6.6g (53%) of (S)-(+)-methadone hydrochloride 
(S)-83 were obtained. 
Rt 12.6 (99.9%) - Racemic - 10.0, 13.1 
Mp 240-241°C [lit. 58 239-241°C] 
[aID +136° (c 2.02, EtOH) 
vrnax(solid)/cm 1 2935 (CH), 2462, 1702 (C=O) 
8H (d6DMSO; 250 MHz) 7.07-7.57 (10 H, m, Car),  3.08 (1 H, brd, 114.0, 
CHCHACHBCPh2), 2.93 (1 H, m, CH3CHCHACHB), 2.67(6 H, brd, N(Cth)2), 
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2.40 (1 H, m, CHCHACHBCPh2), 2.20 (2 H, q, 1 7.3, CH3CH2CO), 0.73 (3 H, t, J 
7.2, CJj3CH2CO),  0.43 (3 H, d, 16.6, CthCH) 
6c (d 6DMSO; 63 MHz) 140.7, 140.3 (ipso-Ar), 129.4, 129.2, 129.0, 128.7, 127.8, 
127.0 (CH,,), 64.8 (CHCH), 59.1 (CPh2CO), 38.5, 38.3 (CHCH2CPh2 and 
N(CH3)2), 32.6 (cH2C0), 14.9, 9.5 (H3CH and cH3CH2) 
rn/z (FAB) 310 (100%, MH), 265 (11, M-N(CH3)2), 154 (19, Ph2), 72 (15, 
CH3CHN(CH3)2) 
Chiral HPLC shows no evidence of (R)-isomer (R)-83, ee >99% 
5.2.3 Lipase screen and chiral CC analysis of the propanoate ester 
5.2.3.1 Preparation of racemic 1-dimethylamino-2-12ropyl propanoate 92 
To a solution of 1-dimethylamino-2-propanol 89 (5g. 48.5 mmol) in 
dichloromethane (125m1) was added slowly with stirring a solution of 
propanoyl chloride (5g, 54.1 mmol) in dichioromethane (75m1). When the 
addition was complete stirring was continued for a further 30 mins and then 
the solvent was removed at reduced pressure to leave the hydrochloride salt 
as a white solid. This was dissolved in water (50ml) and the solution treated 
with saturated sodium hydrogencarbonate solution (50m1). The free base was 
extracted with ethyl acetate (3 x 70m1) and the combined organic layers were 
washed with brine (120ml) and dried (MgSO4). The ethyl acetate was 
removed by rotary evaporation at reduced pressure and the product purified 
by distillation at reduced pressure (bpt 132°C/-10mmHg) to afford a 
colourless oil (5.7g, 74%). 
R t 13.4, 14.0 
S (CDC13 ; 220 MHz) 5.09 (1 H, m, CH3CH(OCOC2H5)), 2.10 -2.60 (4H, m, N-
CH2CH(OCOCthCH3)), 2.25 (6 H, s, N(Cth)2), 1.21 (3 H, d, 16, 
CLI3CH(OCOC2H5)), 1.13(3 H, t, J7.5, OCOCH2CH3) 
93 
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5.2.3.2 Lipase screen for the resolution of 1-dimethylamino-2-12ropanol 89 
Racemic 1-dimethylamino-2-propanol 89 (103mg, 1 mmol) was stirred with 
vinyl propanoate (2m1) and a lipase from the Chirazyme © kit was added. The 
reaction mixture was stirred slowly at room temperature. Periodically the 
reaction mixture was sampled, an aliquot (2 drops) was taken and diluted 
with diethyl ether (lml). The samples were analysed by GC using a chiral
cyclodextrin column. The results are discussed in chapter 4 (4.6). 
5.2.4 Large scale resolution and syntheses of chiral methadones 
5.2.4.1 Resolution of 1-dimethylamino-2-propanol 89 
Me2 N 	 Me2 N 	 + Me2N 
OH 	 OCOC2 H 5 	OH 
Racemic 1-dimethylamino-2-propanol 89 (1003g. 9.74mol) was stirred with 
vinyl propionate (530m1, 4.87mo1) and Novozyme © 435 (30g) was added. The 
reaction mixture was stirred slowly for 70 hours and after this time tic (10% 
methanol/dichioromethane - visualise KMn04 solution) indicated that the 
reaction had gone to 50% conversion. The enzyme was removed by filtration 
and the filtrate was distilled at reduced pressure. (S)-(+)-1-Dimethylamino-2-
propanol (S)-89 was obtained as a colourless oil (450.6g. 45%) bpt 
77°/-15mm, 
Rf (Methanol:dichloromethane, 1:9) 0.16 
vJneat)/cm 1 3419 (OH) 2969, 2819, 2772 (CH) 
8H (CDC13; 250 MHz) 3.78 (1 H, m, CH3CH(OH)), 3.50 (1 H, brs, OH), 2.25 (6 
H, s, N(CH3) 2 ), 2.15 (2 H, m, Nd2) 1.12 (3 H, d, J6.1, CthCH(OH)) 
c (CDC13. 63 MHz) 67.0 (CH(OH)), 63.1 (CH2-N), 45.4 ((cI-13)2N), 20.1 
(CH3CH). 
Experimental 
(R)-(-)-1-Dimethylamino-2-propyl propanoate (R)-92 was the second 
component to distil (557.2g, 36%) bpt 105-108°C / -15mm 
Rf (Methanol:dichloromethane, 1:9) 0.37 
vmax(neat)/cm 1 2978, 2941, 2821, 2768 (CH), 1732 (C=O) 
5H (CDC13. 250 MHz) 5.06 (1 H, m, CH3CH(OCOC2H5)), 2.50(1 H, dd, J 12.7, 
7.2, N-CFjH8CH(OCOC2H5)), 2.30 (3 H, m, N-CHAHBCH(OCOCthCH3)), 
2.25 (6 H, s, N(Cth)2), 1.21 (3 H, d, 16.2, CthCH(OCOC2H5)),  1.12 (3 H, t, I 
7.5, OCOCH2Cth) 
c (CDC13; 63 MHz) 174.0 (C=O), 68.1 (CH-0), 64.0 (CH2-N), 45.8 (LH3)2N), 
27.8 (COCH2CH308.5 (CI-I3CH), 9.0 (COCH2CH3) 
5.2.4.2 (Th-(-')-1-Dimethvlamino-2-12ropanol (R)-89 
Me2 N 
OH 
A solution of sodium methoxide was made by dropping small pieces of 
sodium metal (5g) into methanol (200 ml) under an atmosphere of argon. This 
was then added to a stirred solution of (R)-(-)-1-dimethylamino-2-propyl 
propanoate (R)-92 (557g, 3.5mol) in methanol (3.8L). The mixture was stirred 
overnight and checked for completion by tic (10% methanol! 
dichloromethane). The methanol was removed under reduced pressure and 
the crude (R)-(-)-1-dimethylamino-2-propanol (342g) was purified by 
distillation at reduced pressure, bpt 75°C at -lSmmHg, to afford the title 
compound (R)-89 as a colourless oil (313.1g. 87%). 
Rf (Methanol:dichloromethane, 1:9) 0.18 
vmax(neat)/cm 1 3419(OH)2969,2819,2772(CH) 
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5H (CDC13; 250 MHz) 3.76 (1 H, m, CH3CH(OH)), 3.49 (1 H, brs, OH), 2.24 (6 
H, s, N(CH3)2), 2.15 (2 H, m, Nd2) 1.10 (3 H, d, J6.1, CthCH(OH)) 
öc (CDC13; 63 MHz) 67.0 (CH(OH)), 63.0 (CH2-N), 45.4 (( H3)2N), 20.0 
(CH3CH) 
5.2.4.3 (S)-(+)-1-Dimethylamino-2-chloropropane hydrochloride (S)-9049,66 
Me2 HN 
Cl - 	Cl 
A solution of thionyl chloride (330m1, 4.55mo1) in chloroform (400m1) was 
added slowly, with stirring, to a cooled (ice/water) solution of (R)-(-)-1-
dimethylamino-2 propanol (R)-89 (312.4g. 3.03mol) in chloroform (800m1). 
When the addition was complete a precipitate formed. The mixture was 
allowed to warm to room temperature over 30 minutes and then heated to 
reflux for a further 30 minutes. The precipitate redissolved on heating but 
then the product crystallised out from the boiling solvent as it formed. The 
cooled mixture was diluted with ether (1.5L) and filtered. The crude product 
(440.4g,92%) was recrystallised from 2-propanol and decolourising charcoal 
was used. The product (S)-90 was obtained in 2 crops (328.5g. 69%). 
Mp 192-193° 
[a]D+63.9 0 (c 2.01, H20) 
vmax(so1id)/cm' 2962 (CH) 
3N (D20; 250 MHz)) 4.42 (1 H, sextet, 17.0, CH2CHC1CH3), 3.40 (2 H, d, 18.0, 
NCJ±CHC1), 2.88 (6 H, d, J8.4, N(Cth)2),  1.49 (3 H, d, 16.5, CthCHC 1) 
c (D20; 63 MHz) 64.3 (CHC1), 52.0 (CH2N), 45.6 (CH3N), 41.8 (CH3N), 22.3 
(CH3CH) 
rn/z (FAB) 124 (26.7%, MH, 37Cl), 122 (100, MH, Cl), 86 (8.5, M-CI), 44 (11.0, 
N(CH3) 2 ) 
0 
Experimental 
5.2.4.4 (R)-(-)-2.2-Diphenvl-4-dimethvlaminopentanenitrile (R)-86 55 
CN 
Me2N Ph Ph 
A 50% w/v solution of sodium hydroxide in water (300m1, 7.5mol) was 
added to a mechanically stirred suspension of diphenylacetonitrile (386.5g. 
2.Omol) and dibenzo-18-crown-6 (121g, cat.) in dimethylsuiphoxide (300m1). 
The colour rapidly deepened to an orange/brown. (S)-(+)-1-Dimethylamino-
2-chloropropane hydrochloride (S)-90 (327g. 2.07mol) was added in portions 
over 30 minutes; this caused the temperature to rise and cooling was applied 
(cold water bath) to maintain the temperature below 50°C. After the addition 
was complete the mixture was stirred at 45-50°C (water bath) for a further 
hour. The reaction mixture was then allowed to cool to room temperature and 
was poured into ice/ water (2.5L) and extracted with ethyl acetate (3 x 2L). 
The product was extracted into IN HC1 (2.5L + 1.5L) and this was back 
washed with ethyl acetate. The aqueous was basified with 2M sodium 
hydroxide and extracted with ethyl acetate (3 x 2L). The organic extracts were 
washed with brine (1.5L), dried (MgSO4), and evaporated to give a clear 
yellow oil. This was dissolved in boiling hexane (-3L) and a white solid 
formed as this solution was allowed to cool. The suspension was cooled 
(ice /water) to complete crystallisation and the solid was collected by filtration 
and washed thoroughly with cold hexane (IL). The solid was dried under 
high vacuum and (R)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile (R)-86 
was obtained as a white crystalline solid (197.4g, 34%). 
Mp 100-101 °C 
[a] D -50.2 0 (c 0.71, EtOH) 
vni ax(solid)/cml 2972, 2938, 2819, 2774 (CH), 2229 (CN) 
OYA 
Experinwutal 
6u (CDC13; 250 MHz) 7.38 (10 H, m, CH,), 2.70 (1 H, dd, 113.6, 6.4, 
CHCHACHBCPh2), 2.54 (1 H, sextet, 16.3, CH3CHCHACHB), 2.25 (1 H, dd, J 
13.6, 6.0, CHCHACHBCPh2), 2.15 (6 H, s, N(C)2), 0.92 (3 H, d, 16.5, CthCH) 
öc (CDC13; 63 MHz) 141.2, 140.6 (ipso-Ar), 128.7, 128.6, 127.8, 127.6, 127.3, 
127.1 (CHar), 122.8 N), 55.4 (CH3CH), 49.6 (CPh2CN), 43.2 (N(CH3)2), 39.9 
(CH2), 13.1 (CH3CH) 
m/z (FAB) 289 (4.9%, MH), 279 (100), 154 (23, Ph2), 137 (14), 72 (45, 
CH3CHN(CH3 ) 2 ) 
5.2.4.5 (R)-(-)-Methadone hydrochloride 0-83 30 
Me2N Ph Ph 
All apparatus was dried and the reaction was carried out under an inert 
atmosphere of argon. A solution of (R)-(-)-2,2-diphenyl-4-
dimethylaminopentanenitrile (R)-86 (197.0g, 0.71mol) in toluene (600m1) was 
added to a stirred solution of 3M ethylmagnesium bromide in ether (425ml, 
1.275mol). The ether was removed under reduced pressure and the remaining 
solution heated at reflux (135-140°) for 3 hours. After cooling to room 
temperature 2N HG! (1.5L) was added with care and then stirring was 
continued at 135-140° for a further 30 minutes. The two phases were allowed 
to separate and cool to room temperature. After scratching the sides of the 
flask a solid started to crystallise from the aqueous phase. The flask was 
cooled to complete crystallisation and the white solid was collected by 
filtration. This solid was dried under high vacuum to yield 94g (38%) of 
(R)- (-)-methadonehydrochloride (R)-83 (6-dimethylamino-4,4-diphenyl-3-
heptanone hydrochloride). 
Experin:eiital 
R t 6.3 (94.3%) 8.1 (5.7%) ee = 88.6% [racemic R t 6.5, 8.01 
Mp 230-232°C 
[aID -111.3 0 (c 2.09, EtOH) 
v,(solid)/cm -1 2935 (CH), 2462, 1702 (C=O) 
6H (d6DMSQ; 250 MHz) 7.07-7.57 (10 H, m, Car),  3.08 (1 H, brd, J 14.0, 
CHCHACHBCPh2), 2.93 (1 H, m, CH3CHCHACHB), 2.67(6 H, brd, N(Ca)2), 
2.40 (1 H, m, CHCHACHBCPh2), 2.20 (2 H, q, J 7.3, CH3CH 2CO), 0.73 (3 H, t, J 
7.2, CIj3CH2CO), 0.43 (3 H, d, 16.6, CthCH) 
ö (d 6DMSO; 63 MHz) 140.7, 140.3 (ipso-Ar), 129.4, 129.2, 129.0, 128.7, 127.8, 
127.0 (CHar), 64.8 (CHCH), 59.1 (CPh2CO), 38.5, 38.3 (CHCH2CPh2  and 
N(cH3) 2), 32.6 (CH2CO), 14.9, 9.5 (CH3CH and CH3CH2) 
m/z (FAB) 310(100%, MH), 265 (11, M-N(CH3)2), 154 (19, Ph2), 72 (15, 
CH3CHN(CH3 ) 2 ) 
5.2.4.6 (R)-(-)-1-Dimethylamino-2-chloropropane hydrochloride (R)-9O 4966 
Me2 HN 
Cl - 
This was prepared following the same procedure as the (S)-isomer (5.2.4.3). 
450.6g of (S)-89 were used and 586.2g (84%) of crude product (R)-90 was 
isolated. This was not further purified, 
vmax(solid)/cm 1 2962 (CH) 
8H (D20; 250 MHz)) 4.42 (1 H, sextet, f7.0, CH2CHC1CH3), 3.40 (2 H, d, J8.0, 
NCthCHC1), 2.88 (6 H, d, J8.4, N(Cth)2), 1.49 (3 H, d, J6.5, CthCHC 1) 
I!3J 
Experimental 
5.2.4.7 (S)-('+)-22-Diphenv1-4-dimethylaminopentanenitrile (S)-86 55 
Me2N Ph Ph 
This was prepared following the same procedure as the (R)-isomer (5.2.4.4). 
582.2g of (R)-90 were used and 297.Og (29%) of (S)-(+)-2,2-diphenyl-4-
dimethylaminopentanenitrile (S)-86 were obtained. 
Mp 100-101 °C [lit. 4"1  100-101 °C] 
[aID -50.2 0 (c 0.71, EtOH) [lit. 4949° (c 0.68, EtOH)] 
vmax (solid)/cm' 2972, 2938, 2819, 2774 (CH), 2229 (CN) 
8H (CDC13; 250 MHz) 7.38 (10 H, m, CH,), 2.70 (1 H, dd, 113.6, 6.4, 
CHCLIACHBCPh2), 2.54 (1 H, sextet, 16.3, CH3CHCHACHB), 2.25 (1 H, dd, J 
13.6, 6.0, CHCHACHBCPh2), 2.15 (6 H, s, N(Cth)2), 0.92 (3 H, d, J6.5, CH CH) 
3c (CDCI3; 63 MHz) 141.2, 140.6 (ipso-Ar), 128.7, 128.6, 127.8, 127.6, 127.3, 
127.1 (CH,,), 122.8 N), 55.4 (CH3CH), 49.6 (CPh2CN), 43.2 (N& H3)2),  39.9 
(CH2), 13.1 (CH3CH) 
m/z (FAB) 289 (4.9%, MH), 279 (100), 154 (23, Ph2), 137 (14), 72 (45, 
CH3CHN(CH3)2) 
5.2.4.8 (S)-(+')-Methadone hydrochloride (S')-83 30 
yy`-~ 
Me2N Ph Ph 
All apparatus was dried and the reaction was carried out under an inert 
atmosphere of argon. A solution of (S)-(+)-2,2-diphenyl-4-
dimethylaminopentanenitrile (S)-86 (297g. 1.07mol) in toluene (900ml) was 
added to a stirred solution of 3M ethylmagnesium bromide in ether (650ml, 
100 
Experimental 
1.95mo1). The ether was removed under reduced pressure and the remaining 
solution heated at reflux (135-140°) for 3 hours. After cooling to room 
temperature 2N HCl (1.8L) was added with care and then stirring was 
continued at 135-140° for a further 30 minutes. The two phases were allowed 
to separate and cool to room temperature. After scratching the sides of the 
flask no solid precipitated from solution so the two layers were separated 
and after standing overnight crystals had formed in the toluene layer. The 
suspension was cooled in the fridge for two hours and the solid was collected 
by filtration, washed with cold toluene and dried. 220MHz NMR 
spectroscopy showed this to be (S)-(+)-methadone. It was dissolved in ether 
and treated with 1M ethereal HCl to form the salt. This was collected by 
filtration and dried under high vacuum to yield 51.6g (14%) of (S)-(+)- 
methadone hydrochloride (S)-83 (6-dimethylamino-4,4-diphenyl-3-heptanone 
hydrochloride). 
R t 7.8 (100%) ee >99% [racemic R t 6.5, 8.0] 
Mp 240-241°C 
[aiD +140.5° (c 2.03, EtOH) 
vrnax (solid)/cml 2935 (CH), 2462, 1702 (C=O) 
3H (d6DMSO; 250 MHz) 7.07-7.57 (10 H, m, CH,), 3.08 (1 H, brd, 114.0, 
CHCHACHBCPh2), 2.93 (1 H, m, CH3CHCHACHB), 2.67 (6 H, brd, N(Cth)2), 
2.40 (1 H, m, CHCHACHBCPh2), 2.20 (2 H, q, j 7.3, CH3CJJ2CO),  0.73 (3 H, t, J 
7.2, CLI3CH2CO), 0.43 (3 H, d, 16.6, CUCH) 
3c (d6DMSO; 63 MHz) 140.7, 140.3 (ipso-Ar), 129.4, 129.2, 129.0, 128.7, 127.8, 
127.0 (CHar), 64.8 (CHCH), 59.1 (CPh2CO), 38.5, 38.3 (CHCH2CPh2 and 
N(CH3)2), 32.6 (CH2CO), 14.9, 9.5 (CH3CH and cH3CH2) 
in/z (FAB) 310 (100%, MH+), 265 (11, M-N(CH3)2), 154 (19, Ph2), 72 (15, 
CH3CHN(CH 3 )2 ) 
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Chiral HPLC shows no evidence of (R)-isomer, ee >99%. 
5.2.5 Levo-cx-acetyl methadol (LAAM) 93 
5.2.5.1 6-Dimethvlamino-4,4-diphenvl-3-heptanol 94 prepared by 
hydrogenation 57 
OH 
Me2N Ph Ph 
(S)-(+)-Methadone hydrochloride (S)-83 (200mg, 0.58mmol) was dissolved in 
distilled water (5m1) and platinum (IV) oxide (20mg) was added. This mixture 
was hydrogenated on the Parr apparatus overnight. Tlc (10% 
methanol/dichloromethane) seemed to show complete conversion so the 
catalyst was removed by filtration through celite. The filtrate was basified 
with 2M sodium hydroxide solution and then extracted with ethyl acetate (2 x 
30m1). The combined organic extracts were washed with brine and dried 
(magnesium sulphate). The solvent was removed by evaporation at reduced 
pressure to leave a clear gum (160mg). The 220MHz NMR spectrum (CDC13) 
showed this to be a mixture of methadone and the reduced methadol 94. 
5.2.5.2 6-Dimethylamino-4.4-di42henyl-3-heptanol 94 
OH 
yyl~,_~ 
Me2N Ph Ph 
(S)-(+)-Methadone hydrochloride (S)-83 (600mg, 1.74mmol) was dissolved in 
ethanol (lOmi) and the solution was stirred whilst sodium borohydride 




the addition was complete cerium (III) chloride heptahydrate (5mg, cat.) was 
added. The resultant solution was allowed to stir at room temperature for 30 
minutes then the ethanol was removed under reduced pressure. The residue 
was partitioned between diethyl ether (40m1) and water (40ml). The aqueous 
layer was extracted with more diethyl ether (2 x 20ml) and then the combined 
organics were washed with brine (40ml) and dried (MgSO4). The ether was 
removed under reduced pressure to leave 6-dimethylamino-4,4-diphenyl-3-
heptanol 94 (435mg, 80%). 
oH (220MHz; CDC13 ) 7.1-7.7 (101-1, m, CH.,), 3.85 (11 -1, dd, 110, 3, CUOH), 2.7 
(11-1, dd, J 15, 7, CHCH2CPh 2  ), 2.15 (61-1, s, N(C1i3)2), 1.9-2.3 (21-1, m, 
CHCH2CPh 2 ), 1.75 (1H, m, CH3CHAHB),1.1 (1H,m, CH3CHAHB), 0.8 (6H, m, 
CthCHAHB and  CLI3CH). 
5.2.5.3 6-Dimethylamino-44-diphenyl-3-acetoxyheptane hydrochloride (levo-
-acetyl methadol hydrochloride 93 
CL 
6-Dimethylamino-4,4-diphenyl-3-heptanol 94 (435mg, 1 .4Ommol) dissolved in 
ethyl acetate (lOml) was treated with acetyl chloride (183mg, 2.33mmol). The 
mixture was refluxed for 2 hours. After allowing the solution to cool to room 
temperature the solvent was removed under reduced pressure to leave a 
white foam, this crystallised from ethyl acetate to give 6-dimethylamino-4,4-
diphenyl-3-acetoxyheptane hydrochloride 93 (420mg, 79%). 
103 
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Mp 206-207°C [lit. 67  215°C] 
[aID -56° (c 0.2, H20) [lit. 67  -600 (c 0.2)] 
v rnax (so1id)/cm 1 2974 (CH), 2689, 1725 (C=O) 
3H (CDC13; 250 MHz) 12.03 (1 H, brs, (CH3)2NH), 7.37 (10 H, m, CH), 5.73 (1 
H, dd, J 10.3, 1.5, HCOCOCH3), 3.01 (2 H, m, CHCHACHBCPh2  and 
CHCHACHBCPh2), 2.63 (3 H, d, f4.9, Nd3), 2.53 (3 H, d, J4.9, NCH3), 2.10 (1 
H, m, CHCHACHBCPh2), 2.14 (3 H, s, CH3CO), 1.82 (1 H, m, CH3CHcHij), 
1.00 (1 H, m, CH3CHcfjj), 0.79 (3 H, t, J7.3, CthCHcH0),  0.57(3 H, d, 16.6, 
CthCH) 
3c (CDC13 ; 63 MHz) 171.8 (C=O), 142.3, 140.2 (ipso-Ar), 130.1, 129.2, 128.2, 
128.0, 127.4, 127.2 (CHj, 77.8 (HCOAc), 59.3 (CH3CH), 54.7 (CPh), 41.3, 40.4, 
37.6 (CHCH2CPh 2 and N(CH3)2), 24.4, 21.4 (CH3CO and CH3CH2), 14.3, 10.9 
(CH3CH and CH3CH 2) 
,n/z (FAB) 354 (100%, MH), 154 (26.3, Ph2), 72 (41.1, CH3CHN(CH3)2) 
5.2.5.4 6-Dimethvlamino-4.4-diphenvl-3-heptanol 94 - large scale 
(S)-(+)-Methadone hydrochloride (S)-83 (20g. 57.9mmol) was dissolved in 
ethanol (120m1) and stirred at room temperature. Cerium (III) chloride 
heptahydrate (5mg, cat.) was added before sodium borohydride (140mg, 
3.47mmol) was added portionwise over a period of 30 minutes. The reaction 
was quite exothermic so an ice bath was used to cool the mixture during the 
addition. The resultant solution was stirred at room temperature for 3h then 
the ethanol was removed under reduced pressure. The residue was 
partitioned between dichloromethane (250m1) and water (250m1). The 
aqueous layer was extracted with more dichloromethane (2 x 250m1) and then 
the combined organics were washed with brine (250m1) and dried (MgSO4). 
The dichloromethane was removed under reduced pressure to leave 
6-dimethylamino-4,4-diphenyl-3-heptanol 94 (18.6g. quant.). 
104 
Experimental 
S (220MHz; CDC13) 7.1-7.7 (10H, m, CH,), 3.85 (111, dd, J 10, 3, CHOH), 2.7 
(1H, dd, J 15, 7, CHCH2CPh2 ), 2.15 (6H, s, N(C113)2),  1.9-2.3 (2H, m, 
CHCH2CPh2), 1.75 (1H, m, CH3CHAHB),1.1 (1H, m, CH3CHAUB), 0.8 (6H, m, 
CU3CHAH13 and CthCH). 
5.2.5.5 6-Dimethylamino-4A-diphenvl-3-acetoxvheptane hydrochloride (levo-
(x-acetyl methadol hydrochloride) 93 - large scale 
6-Dimethylamino-4,4-diphenyl-3-heptanol 94 (15.6g, 50.2mmol) dissolved in 
ethyl acetate (150m!) was treated with acetyl chloride (6.57g, 83.7mmo!). The 
mixture was refluxed for 2 hours and a white precipitate formed during this 
period. The resulting suspension was cooled in the fridge overnight. The 
white solid was collected by filtration and the mother liquors reduced to give 
a second crop. The two crops were combined and dried on the rotary 
evaporator (high vacuum) 6-dimethy!amino-4,4-dipheny!-3-acetoxyheptane 
hydrochloride 93 (16.5g, 84%) was obtained as a white solid. 
Mp 212-214°C [lit. 67 215°C] 
[U-ID -60.6 0 (c 0.216, H20)  [lit. 67 -60° (c 0.2)] 
v(solid)/cm-1 2974 (CH), 2689, 1725 (C=O) 
3H (CDC13; 250 MHz) 12.03 (1 H, brs, (CH3)2NH), 7.37 (10 H, m, C), 5.73 (1 
H, dd, 110.3, 1.5, ECOCOCH3), 3.01 (2 H, m, CHCHACHBCPh2 and 
CHCHACHBCPh2), 2.63 (3 H, d, 1 4 .9, NCH3), 2.53 (3 H, d, 1 4 . 9 , NCth), 2.10 (1 
H, m, CHCHACHBCPh2), 2.14 (3 H, s,CH3CO), 1.82 (1 H, m, CH3CHcHi3), 
1.00 (1 H, m, CH3CHjjjj), 0.79 (3 H, t, 1 7 . 3, CthCHcHD), 0.57 (3 H, d, 16.6, 
CthCH) 
6c (CDCI3; 63 MHz) 171.8 (C=O), 142.3, 140.2 (ipso-Ar), 130.1, 129.2, 128.2, 
128.0, 127.4, 127.2 (CH ar), 77.8 (HCOAc), 59.3 (CH3CH), 54.7 (CPh), 41.3, 40.4, 
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37.6 (CHCH2CPh2 and N(CH3) 2 ), 24.4, 21.4 (CI-13C0 and CH3CH2), 14.3, 10.9 
(CH3CH and CH3CH2) 
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